

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2017/066368 A1

(43) International Publication Date

20 April 2017 (20.04.2017)

(51) International Patent Classification:

C07D 413/14 (2006.01) *A61K 31/496* (2006.01)
C07D 413/04 (2006.01) *A61P 25/02* (2006.01)
A61K 31/454 (2006.01) *A61P 25/16* (2006.01)
A61K 31/4439 (2006.01) *A61P 25/28* (2006.01)
A61K 31/5355 (2006.01) *A61P 25/24* (2006.01)

and Province Line Road, Princeton, New Jersey 08543 (US).

(74) Agents: EPPERSON, James et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(21) International Application Number:

PCT/US2016/056716

(22) International Filing Date:

13 October 2016 (13.10.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

3309/DEL/2015 14 October 2015 (14.10.2015) IN

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(72) Inventors: ISLAM, Imadul; 3184 Garrity Way, #333, Richmond, California 94806 (US). THANGATHIRUPATHY, Srinivasan; c/o Syngene International Limited, Biocon Special Economic Zone, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Line Road, Bommasandra, Bangalore, Karnataka 560 099 (IN). WARRIER, Jayakumar Sankara; c/o Syngene International Limited, Biocon Special Economic Zone, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Line Road, Bommasandra, Bangalore, Karnataka 560 099 (IN). CHERUKU, Srinivas; c/o Syngene International Limited, Biocon Special Economic Zone, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Line Road, Bommasandra, Bangalore, Karnataka 560 099 (IN). SHETTY, Poornima; c/o Syngene International Limited, Biocon Special Economic Zone, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Line Road, Bommasandra, Bangalore, Karnataka 560 099 (IN). MACOR, John E.; c/o Bristol-Myers Squibb Company, Route 206

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: SELECTIVE NR2B ANTAGONISTS



(57) Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMD A) receptor and thereby making them useful for the treatment of various disorders of the central nervous system.

SELECTIVE NR2B ANTAGONISTS

CROSS REFERENCE TO RELATED APPLICATION

This application claims the benefit of Indian Provisional Patent Application
5 serial number 3309/DEL/2015 filed October 14, 2015 hereby incorporated by
reference in its entirety.

TECHNICAL FIELD

The disclosure generally relates to compounds of formula I, including their
10 salts, as well as compositions and methods of using the compounds. The compounds
are ligands for the NR2B NMDA receptor and may be useful for the treatment of
various disorders of the central nervous system.

BACKGROUND

15 N-Methyl-D-aspartate (NMDA) receptors are ion channels which are gated by
the binding of glutamate, an excitatory neurotransmitter in the central nervous
system. They are thought to play a key role in the development of a number of
neurological diseases, including depression, neuropathic pain, Alzheimer's disease,
and Parkinson's disease. Functional NMDA receptors are tetrameric structures
20 primarily composed of two NR1 and two NR2 subunits. The NR2 subunit is further
subdivided into four individual subtypes: NR2A, NR2B, NR2C, and NR2D, which
are differentially distributed throughout the brain. Antagonists or allosteric
modulators of NMDA receptors, in particular NR2B subunit-containing channels,
have been investigated as therapeutic agents for the treatment of major depressive
25 disorder (G. Sanacora, 2008, *Nature Rev. Drug Disc.* 7: 426-437).

The NR2B receptor contains additional ligand binding sites in addition to that
for glutamate. Non-selective NMDA antagonists such as Ketamine are pore
blockers, interfering with the transport of Ca^{++} through the channel. Ketamine has
demonstrated rapid and enduring antidepressant properties in human clinical trials as
30 an i.v. drug. Additionally, efficacy was maintained with repeated, intermittent
infusions of Ketamine (Zarate et al., 2006, *Arch. Gen. Psychiatry* 63: 856-864). This
class of drugs, though, has limited therapeutic value because of its CNS side effects,
including dissociative effects.

An allosteric, non-competitive binding site has also been identified in the N-terminal domain of NR2B. Agents which bind selectively at this site, such as Traxoprodil, exhibited a sustained antidepressant response and improved side effect profile in human clinical trials as an i.v. drug (Preskorn et al., 2008, *J. Clin.*


5 Psychopharmacol., 28: 631-637, and F. S. Menniti, et al., 1998, *CNS Drug Reviews*, 4, 4, 307-322). However, development of drugs from this class has been hindered by low bioavailability, poor pharmacokinetics, and lack of selectivity against other pharmacological targets including the hERG ion channel. Blockade of the hERG ion channel can lead to cardiac arrhythmias, including the potentially fatal Torsades de 10 pointe, thus selectivity against this channel is critical. Thus, in the treatment of major depressive disorder, there remains an unmet clinical need for the development of effective NR2B-selective negative allosteric modulators which have a favorable tolerability profile.

15 NR2B receptor antagonists have been disclosed in publications WO01/32615, WO 03/035641, WO2005/035523, WO 2009/006437, and EP1988077.

The disclosure provides technical advantages, for example, the compounds are novel and are ligands for the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system. Additionally, the compounds provide advantages for pharmaceutical uses, for example, with regard to one or more 20 of their mechanism of action, binding, inhibition efficacy, target selectivity, solubility, safety profiles, or bioavailability.

SUMMARY

25 In a first embodiment, the disclosure provides a compound of the formula I



I

where:

30

Ar¹ is phenyl and is substituted with 0-3 substituent selected from cyano, halo, alkyl, haloalkyl and haloalkoxy;

Ar² is phenyl, pyridinyl or pyrimidinyl, and is substituted with 1 OR substituent and
5 with 0-2 halo or alkyl substituents;

R is hydrogen or a prodrug moiety selected from the group consisting of alkyl esters, amino acid esters, alkoxy esters, phosphonic acids, phosphonic alkyl esters, alkoxyphosphonate acid, alkoxyphosphonate alkyl esters, alkyl carbamates, 10 amino acid carbamates, alkyl phosphoramidates, aryl phosphoramidates, and sulfamates;

X is a bond or C₁-C₃ alkylene;

15 n is 1 or 2;

ring A is piperidine, piperazine and is substituted with 0-1 halo substituents;

or a pharmaceutically acceptable salt thereof.

20

DESCRIPTION

It will be understood that any given exemplary embodiment can be combined with one or more additional exemplary embodiments.

Unless specified otherwise, these terms have the following meanings. “Alkyl” means a straight or branched alkyl group composed of 1 to 6 carbons. “Alkenyl” means a straight or branched alkyl group composed of 2 to 6 carbons with at least one double bond. 25 “Alkynyl” means a straight or branched alkyl group composed of 2 to 6 carbons with at least one triple bond. “Cycloalkyl” means a monocyclic ring system composed of 3 to 7 carbons. Terms with a hydrocarbon moiety (e.g. alkoxy) include straight and branched 30 isomers for the hydrocarbon portion. “Halo” includes fluoro, chloro, bromo, and iodo. “Haloalkyl” and “haloalkoxy” include all halogenated isomers from monohalo to perhalo. “Aryl” means a monocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbon atoms, or a bicyclic fused ring system wherein one or both of the rings is a

phenyl group. Bicyclic fused ring systems consist of a phenyl group fused to a four- to six-membered aromatic or non-aromatic carbocyclic ring. Representative examples of aryl groups include, but are not limited to, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl. “Heteroaryl” means a 5 to 7 membered monocyclic or 8 to 11 membered bicyclic aromatic ring system with 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Parenthetic and multiparenthetical terms are intended to clarify bonding relationships to those skilled in the art. For example, a term such as ((R)alkyl) means an alkyl substituent further substituted with the substituent R. The invention includes all pharmaceutically acceptable salt forms of the compounds.

10 Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, glucuronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.

15 Some Formula I compounds contain at least one asymmetric carbon atom, an example of which is shown below. The invention includes all stereoisomeric forms of the compounds, both mixtures and separated isomers. Mixtures of stereoisomers can be separated into individual isomers by methods known in the art. The compounds include all tautomeric forms.

20 The invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include ¹³C and ¹⁴C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds may have a variety of potential uses, for example as standards and reagents in determining biological activity. In the case of

25


stable isotopes, such compounds may have the potential to favorably modify biological, pharmacological, or pharmacokinetic properties.

The abbreviations used in the present application are well-known to those skilled in the art.

5

In a first aspect, a compound of the formula I

10



I

where:

Ar¹ is phenyl and is substituted with 0-3 substituent selected from cyano, halo, alkyl, 15 haloalkyl and haloalkoxy;

Ar² is phenyl, pyridinyl or pyrimidinyl, and is substituted with 1 OR substituent and with 0-2 halo or alkyl substituents;

20 R is hydrogen or a prodrug moiety selected from the group consisting of alkyl esters, amino acid esters, alkoxy esters, phosphonic acids, phosphonic alkyl esters, alkoxyphosphonate acid, alkoxyphosphonate alkyl esters, alkyl carbamates, amino acid carbamates, alkyl phosphoramidates, aryl phosphoramidates, and sulfamates;

25

X is a bond or C₁-C₃ alkylene;

n is 1 or 2;

30 ring A is piperidine, piperazine and is substituted with 0-1 halo substituents;

or a pharmaceutically acceptable salt thereof.

In a second embodiment of the first aspect A compound of claim 1 where Ar¹ is phenyl and is substituted with 0-1 substituent selected from halo and alkyl; Ar² is phenyl, pyridinyl or pyrimidinyl, and is substituted with 1 OR substituent and with 0-2 halo or alkyl substituents; R is hydrogen; X is a bond or C₁-C₃ alkylene; n is 1 or 2; ring A is piperidine, 5 piperazine and is substituted with 0-1 halo substituents; or a pharmaceutically acceptable salt thereof.


In a third embodiment of the first aspect A compound of claim 2 where Ar¹ is phenyl and 10 is substituted with 0-1 substituent selected from halo and alkyl; Ar² is phenyl or pyridinyl, and is substituted with 1 OR substituent and with 0-1 halo substituents; R is hydrogen; X is a methylene; n is 1 or 2; ring A is piperidine or piperazine and is substituted with 0-1 halo substituents; or a pharmaceutically acceptable salt thereof.

15 In a fourth embodiment of the first aspect A compound of claim 1 where n is 1 and ring A is piperazine or piperidine substituted with 0-1 fluoro.

In a fifth embodiment of the first aspect A compound of claim 1 where Ar¹ is phenyl substituted with 0-1 substituents selected from chloro, fluoro and methyl.

20

In a sixth embodiment of the first aspect A compound of claim 1 where Ar² is selected from




25 In a seventh embodiment of the first aspect A compound of claim 1 where X is methylene.

In an eighth embodiment of the first aspect, a compound of formula I where n is 1 and ring A is piperazine or piperidine substituted with 0-1 fluoro.

30


In a ninth embodiment of the first aspect, a compound of formula I where Ar¹ is phenyl substituted with 0-1 substituents selected from chloro, fluoro and methyl.


In a third embodiment of the first aspect, a compound of formula I where Ar² is selected from





In a tenth embodiment of the first aspect, a compound of formula I where X is methylene.

10 In an eleventh embodiment of the first aspect, the compound of formula I is:









or a pharmaceutically acceptable salt thereof.

In a second aspect, a pharmaceutical composition comprising a compound of formula

5 I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

In a third aspect, a method for the treatment of depression, Alzheimer's disease, neuropathic pain, or Parkinson's disease, which comprises administering to a patient

10 a therapeutically affective amount of a compound of formula I.

In a second embodiment of the third aspect, the compound of formula I is directed to the treatment of depression.

15 In a third embodiment of the third aspect, the compound of formula I is directed to the treatment of Alzheimer's disease.

In a fourth embodiment of the third aspect, the compound of formula I is directed to the treatment of neuropathic pain.




5

EXAMPLES

The present disclosure will now be described in connection with certain embodiments which are not intended to limit its scope. On the contrary, the present 10 disclosure covers all alternatives, modifications, and equivalents as can be included within the scope of the claims. Thus, the following examples, which include specific embodiments, will illustrate one practice of the present disclosure, it being understood that the examples are for the purposes of illustration of certain 15 embodiments and are presented to provide what is believed to be the most useful and readily understood description of its procedures and conceptual aspects.

The compounds of the present disclosure may be prepared using the reactions and techniques described in this section, as well as, other synthetic methods known to those of ordinary skill in the art. The reactions are performed in solvents appropriate 20 to the reagents and materials employed and suitable for the transformation being affected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvents, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by 25 one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used.


30 In a preferred embodiment of the invention, the synthesis of the compounds of instant disclosure can be set forth in the following schematic representations – Scheme 1 to scheme 3.

Scheme 1**Scheme 2****Scheme 3**

10

For Scheme 1**Step 1: Ref:** *Chem. Pharm. Bull.* **50**(4) 554—557 (2002)

15




12

To a stirred solution of (R)-4-aminoisoxazolidin-3-one (2.00 g, 19.59 mmol) in THF (30 mL) and Water (10 mL) was added TRIETHYLAMINE (3.28 mL, 23.51 mmol) and Boc₂O (4.55 mL, 19.59 mmol) at RT. The reaction mixture was stirred at RT for 12 h. The completion of the reaction was monitored by LCMS. The reaction mixture was concentrated and was purified by ISCO using 12g silica gel column, the product was eluted at 55% ethyl acetate in pet ether to get (R)-tert-butyl (3-oxoisoxazolidin-4-yl)carbamate (3 g, 14.84 mmol, 76 % yield) as off white solid.

LCMS: Buffer: 10mM Ammonium Acetate pH -5 adjusted with HCOOH, Mobile phase A: Buffer:ACN (95:5), Mobile phase B: Buffer:ACN (5:95), Method: %B: 0min-5%:1.1min -95%:1.7min-95% Column Name: Acquity BEH C18 (2.1 x 50 mm) 1.7 u Method:C:\MassLynx, Flow: 0.8 ml/min, RT-0.54min, M(+1)-147 (t-Butyl cleaved mass).

15 Step 2a : (R)-tert-butyl (2-(4-fluorobenzyl)-3-oxoisoxazolidin-4-yl)carbamate




To a stirred solution of (R)-tert-butyl (3-oxoisoxazolidin-4-yl)carbamate (0.5 g, 2.473 mmol) in DMF (5 mL) was added DIPEA (1.296 mL, 7.42 mmol) and 1-(bromomethyl)-4-fluorobenzene (0.561 g, 2.97 mmol) at RT. The reaction mixture was stirred at RT for 12 h. The completion of the reaction was monitored by LCMS. The reaction mixture was concentrated and was taken for column purification. The crude product was purified by ISCO using 12g silica gel column, the product was eluted with 35% ethylacetate in hexane to get (R)-tert-butyl (2-(4-fluorobenzyl)-3-oxoisoxazolidin-4-yl)carbamate (0.35 g, 1.128 mmol, 45.6 % yield) as off white solid.

LCMS: Buffer: 10mM Ammonium Acetate pH -5 adjusted with HCOOH, Mobile phase A: Buffer:ACN (95:5), Mobile phase B: Buffer:ACN (5:95), Method: %B: 0min-5%:1.1min -95%:1.7min-95% Column Name: Acquity BEH C18 (2.1 x 50 mm) 1.7 u Method:C:\MassLynx, Flow: 0.8 ml/min, RT-0.93min, M(+1)-255 (t-Butyl cleaved mass).

1H NMR: 400 MHz, DMSO-d6: δ 1.40 (s, 9H), 3.92-4.06 (m, 1H), 4.46-4.51 (m, 2H), 4.60-4.71 (m, 3H), 7.11-7.21 (m, 2H), 7.33-7.36 (m, 2H), 7.51 (d, J = 8.40 Hz, 1H).

5 **Step 2b : (R)-tert-butyl (2-(4-methylbenzyl)-3-oxoisoxazolidin-4-yl)carbamate**




To a stirred solution of (R)-tert-butyl (3-oxoisoxazolidin-4-yl)carbamate (0.5 g, 2.473 mmol) in DMF (5 mL) was added DIPEA (1.296 mL, 7.42 mmol) and 1-(bromomethyl)-4-methylbenzene (0.549 g, 2.97 mmol) at RT. The reaction mixture 10 was stirred at RT for 12 hrs. The completion of the reaction was monitored by LCMS. The reaction mixture was concentrated to remove DMF and the crude 1.1g as such was taken for column purification. The crude product was purified by ISCO using 12g silica gel column and was eluted with 21% ethylacetate in pet ether to get (R)-tert-butyl (2-(4-methylbenzyl)-3-oxoisoxazolidin-4-yl)carbamate (0.3 g, 0.979 15 mmol, 39.6 % yield) as off white solid.

LCMS: Column-Ascentis Express C18 (50X2.1mm-2.7 μ m), Mphase A : 10mM NH4COOH IN WATER:ACN(98:02), Mphase B : 10mM NH4COOH IN WATER:ACN(02:98), Flow = 1ML/MIN, RT-2.156min, M(-1)-305.

1H NMR: 400 MHz, DMSO-d6: δ 1.40-0.00 (m, 9H), 2.29 (s, 3H), 3.85-3.90 (m, 1H), 4.44-4.49 (m, 1H), 4.55-4.65 (m, 3H), 7.14-7.20 (m, 4H), 7.49 (d, J = 8.80 Hz, 1H).

Chiral screening: Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralpak AD H (250 X 4.6)mm 5u, Column Temperature : 23, Total Flow : 3, CO2 Flow Rate : 1.95, Co-Solvent Flow Rate : 1.05, Co-Solvent % : 35, 25 Back Pressure : 102, RT -3.58min, 93% pure.

Step3a: (R)-4-amino-2-(4-fluorobenzyl)isoxazolidin-3-one.hydrochloride.




To a stirred solution of (R)-tert-butyl (2-(4-fluorobenzyl)-3-oxoisoxazolidin-4-yl)carbamate (0.4 g, 1.289 mmol) in 1,4-Dioxane (10 mL) was added 4M HCl in 1,4-Dioxane (2 mL, 8.00 mmol) at RT. The reaction mixture was stirred at RT for 2 h. Major desired product mass by LCMS, the reaction mixture was concentrated to get (R)-4-amino-2-(4-fluorobenzyl)isoxazolidin-3-one hydrochloride (0.25 g, 1.014 mmol, 79 % yield) as off white solid.

10 **LCMS:** Column-Ascentis Express C18 (50X2.1mm-2.7 μ m), Mphase A : 10mM NH₄COOH IN WATER:ACN(98:02), Mphase B : 10mM NH₄COOH IN WATER:ACN(02:98), Flow = 1ML/MIN, RT-1.681min, M(+1)-211.

15 **1H NMR:** 400 MHz, DMSO-d₆: δ 4.22 (t, J = 19.60 Hz, 1H), 4.56-4.81 (m, 4H), 7.18-7.24 (m, 2H), 7.36-7.41 (m, 2H), 9.03 (s, 3H).

Step 3b: (R)-4-amino-2-(4-methylbenzyl)isoxazolidin-3-one, HCl




20 To a stirred solution of (R)-tert-butyl (2-(4-methylbenzyl)-3-oxoisoxazolidin-4-yl)carbamate (0.25 g, 0.816 mmol) in 1,4-Dioxane (5 mL) was added 4M HCl in 1,4-Dioxane(4M) (2 mL, 8.00 mmol) at RT. The reaction mixture was stirred at RT for 2 h. Major desired product mass by LCMS. The completion of the reaction was monitored by LCMS. The reaction mixture was concentrated under vaccum to get (R)-4-amino-2-(4-methylbenzyl)isoxazolidin-3-one, HCl (0.18 g, 0.742 mmol, 91 % yield) as off white solid.

25 **LCMS:** Column-Ascentis Express C18 (50X2.1mm-2.7 μ m), Mphase A : 10mM NH₄COOH IN WATER:ACN(98:02), Mphase B : 10mM NH₄COOH IN WATER:ACN(02:98), Flow = 1ML/MIN, RT-1.755min, M(+1)-207.

1H NMR: 400 MHz, DMSO-d6: δ 2.30 (s, 3H), 4.16-4.20 (m, 1H), 4.57-4.65 (m, 2H), 4.69-4.70 (m, 2H), 7.17-7.23 (m, 5H), 8.96 (bs, 3H).

Synthesis of 3-(4-methoxyphenyl)pentane-1,5-diyI dimethanesulfonate

5




To a stirred solution of 3-(4-methoxyphenyl)pentane-1,5-diol (0.8 g, 3.80 mmol) in DCM (10 mL) was added PYRIDINE (0.923 mL, 11.41 mmol) at 0 °C. 10 The reaction mixture was stirred at RT for 15 minutes and was added Mesyl-Cl (0.652 mL, 8.37 mmol) at 0 °C and stirred at RT for 12 h. The reaction mixture was added water 100ml, the product was extracted with DCM (3*50 mL), the combined organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get brown crude material 1.5g. The crude was purified by isco using 12g silica gel 15 column, the product was eluted with 25% ethylacetate in hexane to get 3-(4-methoxyphenyl)pentane-1,5-diyI dimethanesulfonate (0.1 g, 0.273 mmol, 7.17 % yield) as colorless gummy.

1H NMR: 400 MHz, DMSO-d6: δ 1.91-2.10 (m, 4H), 2.78-2.82 (m, 1H), 3.10 (s, 6H), 3.73 (s, 3H), 3.88-3.94 (m, 2H), 4.01-4.06 (m, 2H), 6.90 (d, J = 8.40 Hz, 2H), 20 7.18 (d, J = 8.40 Hz, 2H).

For Scheme 2:

Step 1a: 4-bromo-2-(4-fluorobenzyl)isoxazolidin-3-one




To a stirred solution of KBr (1.351 g, 11.35 mmol) and HBr in water (3 mL, 22.10 mmol) in Water (7 mL) was cooled to 0 °C temperature was added (R)-4-amino-2-(4-fluorobenzyl)isoxazolidin-3-one, HCl (0.7 g, 2.84 mmol) after 10 min,

the reaction mixture was added SODIUM NITRITE (0.431 g, 6.24 mmol) in water(2 mL) slowly drop wise at 0 °C. The reaction mixture was stirred at RT for 1 h. The reaction mixture was added 10% sodium bicarbonate solution (10 mL), the product was extracted with ethyl acetate (3*10mL), the combined organic layer was dried over anhydrous sodium sulphate , filtered and concentrated to get crude 0.8g. The crude was purified by ISCO using 12g silica gel column, the product was eluted with 35% ethyl acetate in pet ether to get 4-bromo-2-(4-fluorobenzyl)isoxazolidin-3-one (0.3 g, 0.876 mmol, 30.9 % yield) as colorless gummy material.

10 **LCMS:** Buffer:10mM AmmoniumAcetate pH -5 adjusted with HCOOH, Mobile phase A:Buffer:ACN (95:5), Mobile phase B:Buffer:ACN (5:95), Method:%B: 0min-5%:1.1 min -95%:1.7min-95%Column Name: Acquity BEH C18 (2.1 x 50 mm) 1.7 u Method:C:\MassLynx, Flow: 0.8 ml/min, RT- 0.84 min, M(+1)-274.

15 **1H NMR:** 400 MHz, DMSO-d6: δ 4.44-4.47 (m, 1H), 4.63-4.68 (m, 1H), 4.73 (d, J = 4.40 Hz, 2H), 5.08-5.10 (m, 1H), 7.18-7.23 (m, 2H), 7.34-7.38 (m, 2H).

Step 1b: 4-bromo-2-(4-methylbenzyl)isoxazolidin-3-one




20 To a stirred solution of KBr (1.961 g, 16.48 mmol) and HBr (4 ml, 73.7 mmol) in Water (10 mL) was cooled to 0 °C temperature was added (R)-4-amino-2-(4-methylbenzyl)isoxazolidin-3-one, HCl (1 g, 4.12 mmol) after 10 min, the reaction mixture was added SODIUM NITRITE (0.625 g, 9.06 mmol) in water(2 mL) slowly drop wise at 0 °C. The reaction mixture was stirred at RT for 1 h. The completion of 25 the reaction was monitored by LCMS. The reaction mixture was added 10% sodium bicarbonate solution (10 mL), the product was extracted with ethyl acetate (3*10 mL), the combined organic layer was dried over anhydrous sodium sulphate , filtered and concentrated to get crude 1.1g. The crude compound was purified by ISCO using 12g silica gel column, the product was eluted with 15% ethyl acetate in pet

ether to get 4-bromo-2-(4-methylbenzyl)isoxazolidin-3-one (0.5 g, 1.851 mmol, 44.9 % yield) as colorless gummy material.

5 **1H NMR:** 400 MHz, DMSO-d6: δ 2.04 (s, 3H), 4.42-4.46 (m, 2H), 4.60-4.68 (m, 3H), 5.05-5.10 (m, 2H), 7.18 (d, J = 2.40 Hz, 4H).

For Scheme 3:

Step 1a: Synthesis of tert-butyl (tert-butoxycarbonyl)oxy(4-methylbenzyl)carbamate




10

To a solution of tert-butyl (tert-butoxycarbonyl)oxy carbamate (0.347 g, 1.486 mmol) and 1-(bromomethyl)-4-methylbenzene (0.25 g, 1.351 mmol) in DCM (5 mL) was added NaOH (1.486 mL, 1.486 mmol) followed by tetrabutylammonium bromide (0.435 g, 1.351 mmol) and stirred at RT for overnight. The completion of 15 the reaction was monitored by TLC. The reaction mixture was added water (50 mL) and extracted with DCM (2x 25 mL), the combined organic layer was dried over sodium sulphate and concentrated under reduced pressure to get tert-butyl (tert-butoxycarbonyl)oxy(4-methylbenzyl)carbamate (0.4 g, 1.162 mmol, 86 % yield) as colorless liquid.

20 **1H NMR:** 400 MHz, DMSO-d6: δ 1.42 (s, 18H), 2.29 (s, 3H), 4.66 (s, 2H), 7.16 (s, 4H).

Step 1b: Synthesis of tert-butyl (tert-butoxycarbonyl)oxy(4-chlorobenzyl)carbamate.




25

To a solution of tert-butyl (tert-butoxycarbonyl)oxycarbamate (2.497 g, 10.71 mmol) and 1-(bromomethyl)-4-chlorobenzene (2 g, 9.73 mmol) in DCM (25 mL) was added NaOH (10.71 mL, 10.71 mmol) followed by TETRABUTYLLAMMONIUM BROMIDE (3.14 g, 9.73 mmol) stirred at RT for 5 overnight. The reaction mixture was added water (100 mL) and the product was extracted with ethylacetate (3*100 mL), the combined organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get crude 5.4g. The crude was purified by ISCO using 40g silica gel column, the product was eluted with 10% ethylacetate in pet ether to get tert-butyl (tert-butoxycarbonyl)oxy(4-chlorobenzyl)carbamate (3.1 g, 8.66 mmol, 89 % yield) as colorless gummy material.

10 **1H NMR:** 300 MHz, DMSO-d6: δ 1.42 (s, 18H), 4.69 (s, 2H), 7.16-7.22 (m, 2H), 7.31-7.34 (m, 2H).


15 **Step 1c: Synthesis of tert-butyl (tert-butoxycarbonyl)oxy(4-fluorobenzyl)carbamate.**



20 To a solution of tert-butyl (tert-butoxycarbonyl)oxycarbamate (2.71 g, 11.64 mmol) and 1-(bromomethyl)-4-fluorobenzene (2 g, 10.58 mmol) in DCM (25 mL) was added NaOH (11.64 mL, 11.64 mmol) followed by TETRABUTYLLAMMONIUM BROMIDE (3.41 g, 10.58 mmol) stirred at RT for 25 overnight. The reaction mixture was added water (100 mL) and the product was extracted with ethyl acetate (3*100 mL), the combined organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get crude 5.5g. The crude was purified by ISCO using 40g silica gel column, the product was eluted with 10% ethyl acetate in pet ether to get tert-butyl (tert-butoxycarbonyl)oxy(4-fluorobenzyl)carbamate (3.1 g, 8.99 mmol, 85 % yield) as colorless gummy material.

1H NMR: 300 MHz, DMSO-d6: δ 1.42 (s, 18H), 4.69 (s, 2H), 7.16-7.22 (m, 2H), 7.31-7.34 (m, 2H).


5 **Step 2a: Synthesis of N-(4-methylbenzyl)hydroxylamine, HCl**



To a solution of tert-butyl (tert-butoxycarbonyl)oxy(4-methylbenzyl)carbamate (0.25 g, 0.741 mmol) in 1,4-Dioxane (3 mL) was added 4M HCl in Dioxane (3 mL, 12.00 mmol) and stirred at RT for overnight. The completion of the reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure. Then washed with ethyl acetate, filtered and dried to get N-(4-methylbenzyl)hydroxylamine, HCl (0.13g, 0.864 mmol, 97 % yield) as off white solid.

15 **1H NMR:** 400 MHz, DMSO-d6: δ 2.32 (s, 3H), 4.25 (s, 2H), 7.22 (d, J = 8.00 Hz, 2H), 7.39 (d, J = 8.00 Hz, 2H), 10.91 (s, 1H), 11.62 (s, 1H).

Step 2b: Synthesis of N-(4-chlorobenzyl)hydroxylamine, HCl




To a stirred solution of tert-butyl (tert-butoxycarbonyl)oxy(4-chlorobenzyl)carbamate (4 g, 11.18 mmol) in 1,4-Dioxane (30 mL) was added 4M HCl in 1,4-Dioxane (15 mL, 11.18 mmol) at RT. The reaction mixture was stirred at

RT for 18 h. The reaction mixture was concentrated to get N-(4-chlorobenzyl)hydroxylamine, HCl (1.8 g, 9.28 mmol, 83 % yield) as off white solid.

1H NMR: 400 MHz, DMSO-d6: δ 4.33 (d, J = 6.40 Hz, 2H), 7.49-7.52 (m, 2H), 7.54-7.57 (m, 2H), 10.97 (s, 1H), 11.80 (s, 2H).

Step 2c: Synthesis of N-(4-fluorobenzyl) hydroxylamine, HCl




10 To stirred solution of tert-butyl (tert-butoxycarbonyl)oxy(4-fluorobenzyl)carbamate (4 g, 11.72 mmol) in 1,4-Dioxane (30 mL) was added 4M HCl in 1,4-Dioxane (15 mL, 11.72 mmol) at RT. The reaction mixture was stirred at RT for 12 h. The reaction mixture was concentrated to get N-(4-fluorobenzyl)hydroxylamine, HCl (1.5 g, 8.45 mmol, 72.1 % yield) as off white solid.

15

1H NMR: 400 MHz, DMSO-d6: δ 4.31 (s, 2H), 7.23-7.29 (m, 2H), 7.54-7.58 (m, 2H), 10.92 (s, 1H), 11.67 (s, 2H).

20 **Step 3a: Synthesis of 4-bromo-2-(4-methylbenzyl)-1,2-oxazinan-3-one**



25 To a solution of N-(4-methylbenzyl)hydroxylamine, HCl (0.15 g, 0.864 mmol) in DCM (5 mL) and NaOH (0.038 g, 0.950 mmol) in Water (1 mL) cooled to 5 °C was added 2,4-dibromobutanoyl chloride (0.126 mL, 0.950 mmol) drop wise and additional 50 % aqueous NaOH (0.038 g, 0.950 mmol) solution at 5 °C. The reaction

mixture was stirred at 5 °C for 2hrs. Then again 50% aqueous NaOH (0.038 g, 0.950 mmol) solution was added at 5 °C and the reaction mixture was stirred at RT for 16 h. The completion of the reaction was monitored by LCMS. The reaction mass was diluted with water (25 mL) and the product was extracted with DCM (2x 25 mL), the 5 combined organic layer was dried over sodium sulphate, filtered and concentrated under reduced pressure to get crude 0.2g. The crude was purified by ISCO (15%EA:Hexane ,12g silica gel column) to get 4-bromo-2-(4-methylbenzyl)-1,2-oxazinan-3-one (0.07 g, 0.224 mmol, 26.0 % yield) as colorless gummy material.


10 **LCMS :**Column-Ascentis Express C18 (50X2.1mm-2.7μm), Mphase A : 2%ACN - 98 %H2O-10mM NH4C00H, Mphase B : 98%ACN - 2 %H2O-10mM

NH4C00H,Flow = 1ML/MIN

Time :%B :: 0.0 : 0.0 :: 1.7 : 100.0 :: 3.4 : 100.0, RT:1.89min ; (M+H):284.


15 **1H NMR:** 300 MHz, DMSO-d6: δ 2.19-2.26 (m, 1H), 2.29 (s, 3H), 2.65-2.72 (m, 1H), 3.98-4.14 (m, 1H), 4.72 (s, 2H), 4.91-4.95 (m, 1H), 7.14-7.21 (m, 4H).

Step 3b: Synthesis of 4-bromo-2-(4-chlorobenzyl)morpholin-3-one



20 **LCMS:** Column-Ascentis Express C18 (50X2.1mm-2.7μm), Mphase A : 10mM NH4C00H IN WATER:ACN(98:02), Mphase B : 10mM NH4C00H IN WATER:ACN(02:98), Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.7 : 100.0 :: 3.0 : 100.0 :: 3.2 : 0.0, RT -2.148min, (M+1)-304.

25 **Step 3c: Synthesis of 4-bromo-2-(4-fluorobenzyl)morpholin-3-one**



LCMS: Column-Ascentis Express C18 (50X2.1mm-2.7μm), Mphase A : 10mM NH4C00H

Mphase B : CAN, Flow = 1ML/MIN, Time : %B :: 0.0 : 50 :: 1.7 : 100.0 :: 4.0 : 100.0,
 RT - 2.123 min, (M+1) – 288.

5 **Example 1 (P1 & P2)**



To a stirred solution of (R)-4-amino-2-(4-fluorobenzyl)isoxazolidin-3-one (0.092 g, 0.437 mmol) in ACN (2 mL) was added DIPEA (0.381 mL, 2.183 mmol) and 3-(4-methoxyphenyl)pentane-1,5-diyl dimethanesulfonate (0.16 g, 0.437 mmol) at RT. The reaction mixture was stirred at 90° C in pressure tube for 12 h. Major desired product mass by LCMS. The reaction mixture was concentrated to that residue was added water (50 ml), the product was extracted with ethylacetate (3*25 mL). The combined organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get (R)-2-(4-fluorobenzyl)-4-(4-(4-methoxyphenyl)piperidin-1-yl)isoxazolidin-3-one (0.15 g, 0.125 mmol, 28.6 % yield) with LCMS purity 32% as brown gummy material. The crude as such was taken for next step without further purification.

LCMS: Buffer: 10mM AmmoniumAcetate pH -5 adjusted with HCOOH, Mobile phase A: Buffer:ACN (95:5), Mobile phase B: Buffer:ACN (5:95), Method: %B: 0min-5%:1.1min -95%:1.7min-95% Column Name: Acuity BEH C18 (2.1 x 50 mm) 1.7 u Method:C:\MassLynx, Flow: 0.8 ml/min, RT-1.09min, M(+1)- 385.

To a stirred solution of 2-(4-fluorobenzyl)-4-(4-(4-methoxyphenyl)piperidin-1-yl)isoxazolidin-3-one (0.15 g, 0.125 mmol) in DCM (10 mL) was added BBR₃ (2 mL, 21.16 mmol) at -78°C temperature. The reaction mixture was stirred at -78°C for 30 minutes. Major desired product mass by LCMS. The reaction mixture was quenched with 10% NaHCO₃ 50ml and the product was extracted with DCM (3*25 mL). The combined organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get crude 0.16g. The crude product was purified by HPLC to get 1 2-(4-fluorobenzyl)-4-(4-(4-hydroxyphenyl)piperidin-1-yl)isoxazolidin-3-one (22mg, 0.059 mmol, 47.6%) as off white solid.

Chiral hplc of the example 1 shown two peaks and the racemic mixture was separated by Chiral HPLC/SFC to get **P1** and **P2**.

5 **Example 1 (Racemic mixture): LCMS 1:** A: 95% Water: 5% Acetonitrile;10mM NH4OAC, B: 5% Water:95% Acetonitrile;10mM NH4OAC, Flow: 1.1 ml/min, Temp :50°C, Column: Ascentis Express C18 (50x2.1)mm ,2.7µm, Time (min) : 0---3, %B : 0---100,rt-1.495min, M(+1)-371.

10 **Example 1 (Racemic mixture): LCMS 2 :** A: 95% Water: 5% Acetonitrile;0.1%TFA, B: 5% Water:95% Acetonitrile;0.1%TFA, Flow: 1.1 ml/min, Temp :50°C, Column: Ascentis Express C18 (50x2.1)mm ,2.7µm, Time (min) : 0---3,%B : 0---100. RT-0.951min, M(+1)-371.


15 **Example 1 (Racemic mixture): 1H NMR:** 400 MHz, MeOD: δ 1.90-1.98 (m, 2H), 2.07-2.11 (m, 2H), 2.76-2.80 (m, 1H), 3.11-3.17 (m, 1H), 3.42-3.51 (m, 2H), 3.90-3.92 (m, 1H), 4.59-4.73 (m, 3H), 4.80-4.86 (m, 2H), 6.76-6.78 (m, 2H), 7.08-7.15 (m, 4H), 7.40-7.44 (m, 2H).

20 **Chiral hplc :** Injection Volume :10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralpak AD H (250 X 4.6)mm 5u, Column Temperature : 22.9, Total Flow : 3, CO2 Flow Rate : 1.65, Co-Solvent Flow Rate : 1.35, Co-Solvent % : 45, Back Pressure : 101, Two diastereomer peaks were separated at RT1:3.03 min, 36.4% and RT2- 8.21min, 63.5%.

25 **Preparative SFC Conditions:**

Column/dimensions: Chiralpak AD-H (250 X 21)mm,5u, % CO2: 55%, % Co solvent: 45% (0.3%DEA in Methanol), Total Flow: 60.0g/min, Back Pressure: 100bar, Temperature: 25°C, UV: 220nm, Solubility: Methanol 600.0ml, Loadability/Inj: 6.0mg/mL Total No of injections: 5, Total Time for purification 30 1.0hrs.

For P-1(Homochiral):




LCMS: Column-XBridge BEH C18 (50X4.6mm-5 μ m), Mphase A : 2%ACN - 98 %H2O-10mM NH4C00H Mphase B : 98%ACN - 2 %H2O-10mM NH4C00H, Flow = 0.8ML/MIN, Time:%B::0.0 : 10:: 7 : 100.0 :: 15 : 100.0, RT-1.979min, M(+1)-371.

5 **1H NMR:** 400 MHz, DMSO-d6: δ 1.49-1.56 (m, 2H), 1.68 (d, J = 12.40 Hz, 2H), 2.27-2.35 (m, 2H), 2.72-2.81 (m, 2H), 3.08 (d, J = 10.80 Hz, 1H), 3.81-3.85 (m, 1H), 4.20-4.24 (m, 1H), 4.35 (t, J = 17.60 Hz, 1H), 4.65 (s, 2H), 6.66 (t, J = 8.80 Hz, 2H), 7.00 (d, J = 8.40 Hz, 2H), 7.16-7.20 (m, 2H), 7.32-7.36 (m, 2H), 9.18 (bs, 1H).

10 **Chiral SFC:** Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralpak AD H (250 X 4.6)mm 5u, Column Temperature :23.9, Total Flow :3 , CO2 Flow Rate : 1.65, Co-Solvent Flow Rate: 1:35, Co-Solvent % :45, Back Pressure : 100, RT-2.99min.

15 **For P-2(Homochiral):**




LCMS: A: 95% Water: 5% Acetonitrile;10mM NH4OAC,B: 5% Water:95%, Acetonitrile;10mM NH4OAC,Flow: 1.1 ml/min, Temp :50°C, Column: Ascentis Express C18 (50x2.1)mm ,2.7 μ m, Time (min) : 0---3, %B : 0---100 RT-1.450min,

20 M(+1)-371.

25 **1H NMR:** 400 MHz, MeOD: δ 1.68-1.81 (m, 4H), 2.43 (d, J = 26.40 Hz, 2H), 2.84-2.92 (m, 2H), 3.20-3.26 (m, 1H), 3.89-3.92 (m, 1H), 4.32-4.36 (m, 1H), 4.42-4.47 (m, 1H), 4.73 (d, J = 5.60 Hz, 2H), 6.71-6.73 (m, 2H), 7.04-7.12 (m, 4H), 7.37-7.41 (m, 2H), 9.18 (s, 1H).


Chiral SFC : Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralpak AD H (250 X 4.6)mm 5u, Column Temperature :23.9, Total Flow :3 , CO2 Flow Rate : 1.65, Co-Solvent Flow Rate: 1:35, Co-Solvent % :45, Back Pressure : 100, RT-7.88min.

Example 2 (P1 & P2)

To a stirred solution of 3-(4-methoxyphenyl)pentane-1,5-diyl dimethanesulfonate (0.25 g, 0.682 mmol) in ACN (3 mL) was added (R)-4-amino-2-(4-methylbenzyl)isoxazolidin-3-one, HCl (0.166 g, 0.682 mmol) and DIPEA (0.357 mL, 2.047 mmol) at RT. The reaction mixture was stirred at 120 °C for 18h in pressure tube. 14% expected product mass by LCMS. The reaction mixture was concentrated to remove ACN and was added water 50ml, the product was extracted with ethylacetate (3*25 mL), the combined organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get crude 0.4g. The crude product as such was taken for next step without further purification.

LCMS: Buffer: 10mM AmmoniumAcetate pH -5 adjusted with HCOOH, Mobile phase A: Buffer:ACN (95:5), Mobile phase B: Buffer:ACN (5:95), Method: %B: 15 Omin-5%:1.1min -95%:1.7min-95% Column Name: Acquity BEH C18 (2.1 x 50 mm) 1.7 u Method:C:\MassLynx, Flow: 0.8 ml/min, RT-1.10 min, M(+1)-381. To a stirred solution of 4-(4-(4-methoxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)isoxazolidin-3-one (0.2 g, 0.526 mmol) in DCM (10 mL) was added BBR3 (2 mL, 21.16 mmol) at -78°C temperature. The reaction mixture was stirred at -78°C for 30 minutes. 19% desired product mass by LCMS. The reaction mixture was quenched with 10% NaHCO3 50ml and the product was extracted with DCM 3*25 ml, the combined organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get crude 0.16g. The crude product was purified by HPLC to get **2** 4-(4-(4-hydroxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)isoxazolidin-3-one (42mg, 0.115 mmol, 21.8%) as pale yellow solid. Chiral hplc of the example **2** shown two peaks and the racemic mixture was separated by Chiral HPLC/SFC to get **P1** and **P2**


Example 2 (Racemic mixture): 1H NMR: 400 MHz, MeOD: δ 1.68-1.80 (m, 4H), 30 2.34 (s, 3H), 2.39-2.48 (m, 2H), 2.81-2.95 (m, 2H), 3.74-3.20 (m, 1H), 3.87-3.91 (m, 1H), 4.31-4.35 (m, 1H), 4.40-4.45 (m, 1H), 4.64-4.74 (m, 2H), 6.71-6.73 (m, 2H), 7.17-7.25 (m, 4H).

For P1 (Homochiral):

LCMS: A: 95% Water: 5% Acetonitrile; 10mM NH4OAC, B: 5% Water:95%
 5 Acetonitrile; 10mM NH4OAC, Flow: 1.1 ml/min, Temp :50°C, Column: Ascentis Express C18 (50x2.1)mm ,2.7μm, Time (min) : 0---3, %B : 0---100, RT-1.563min, M(+1)-367.

1H NMR: 400 MHz, MeOD: δ 1.68-1.80 (m, 4H), 2.34 (s, 3H), 2.39-2.45 (m, 2H),
 10 2.84-2.92 (m, 2H), 3.17 (t, J = 26.00 Hz, 1H), 3.87-3.91 (m, 1H), 4.31-4.45 (m, 2H),
 4.58-4.74 (m, 2H), 6.71-6.73 (m, 2H), 7.04-7.06 (m, 2H), 7.17-7.25 (m, 4H).

Chiral SFC: Injection Volume: 10, Co-Solvent: 0.3% DEA in Methanol, Column: Chiralpak AD H (250 X 4.6)mm 5u, Column Temperature: 22.9, Total Flow : 4, CO2
 15 Flow Rate : 2.4, Co-Solvent Flow Rate : 1.6, Co-Solvent % : 40, Back Pressure : 100 , RT- 3.11 min.

For P2 (homochiral):


20 **LCMS:** A: 95% Water: 5% Acetonitrile; 10mM NH4OAC, B: 5% Water:95%
 Acetonitrile; 10mM NH4OAC, Flow: 1.1 ml/min, Temp :50°C, Column: Ascentis Express C18 (50x2.1)mm ,2.7μm, Time (min) : 0---3, %B : 0---100, RT-1.566min, M(+1)-367.

25 **1H NMR:** 400 MHz, MeOD: δ 1.68-1.80 (m, 4H), 2.34 (s, 3H), 2.40-2.45 (m, 2H),
 2.84-2.92 (m, 2H), 3.18-3.20 (m, 1H), 3.87-3.91 (m, 1H), 4.31-4.45 (m, 2H), 4.64-4.86 (m, 2H), 6.71-6.73 (m, 2H), 7.04-7.06 (m, 2H), 7.17-7.25 (m, 4H).

Chiral SFC: Injection Volume: 10, Co-Solvent: 0.3% DEA in Methanol, Column : Chiralpak AD H (250 X 4.6)mm 5u, Column Temperature: 22.9, Total Flow : 4, CO2 Flow Rate : 2.4, Co-Solvent Flow Rate : 1.6, Co-Solvent % : 40, Back Pressure : 99 , RT- 6.85min.

5

Example 3 (Racemic mixture):



10 To a stirred solution of 4-bromo-2-(4-fluorobenzyl)isoxazolidin-3-one (0.031 g, 0.112 mmol) in DMF (2 mL) was added DIPEA (0.059 mL, 0.337 mmol) and 6-(piperidin-4-yl)pyridin-3-ol (0.02 g, 0.112 mmol) at RT. The reaction mixture was stirred at RT for 18 h. 32% Desired product mass by LCMS. The reaction mixture was purified by HPLC to get 2-(4-fluorobenzyl)-4-(4-(5-hydroxypyridin-2-yl)piperidin-1-yl)isoxazolidin-3-one (2.2 mg, 5.86 μ mol, 5.23 % yield) as pale yellow solid.

15

LCMS (Ammonium acetate method) : A: 95% Water: 5% Acetonitrile; 10mM NH4OAC, B: 5% Water: 95% Acetonitrile; 10mM NH4OAC, Flow: 1.1 ml/min, Temp : 50°C, Column: Ascentis Express C18 (50x2.1)mm, 2.7 μ m, Time (min) : 0---3, %B : 0---100, RT-1.159 min, M(+1)-372.


LCMS (TFA method) : A: 95% Water: 5% Acetonitrile; 0.1%TFA, B: 5% Water: 95% Acetonitrile; 0.1%TFA, Flow: 1.1 ml/min, Temp : 50°C, Column: Ascentis Express C18 (50x2.1)mm, 2.7 μ m, Time (min) : 0---3, %B : 0---100, RT- 0.675 min, M(+1)-372.

1H NMR: 400 MHz, DMSO-d6: δ 1.61-1.65 (m, 2H), 1.74-1.77 (m, 2H), 2.30-2.33 (m, 1H), 2.51-2.55 (m, 1H), 2.73-2.74 (m, 1H), 2.79-2.82 (m, 1H), 3.16-3.18 (m, 1H), 3.81-3.85 (m, 1H), 4.20-4.24 (m, 1H), 4.35-4.37 (m, 1H), 4.65 (s, 2H), 7.07-

7.07 (m, 2H), 7.16-7.20 (m, 2H), 7.32-7.36 (m, 2H), 8.03 (d, J = 3.60 Hz, 1H), 9.64 (s, 1H).

Example 4 (Racemic mixture):


5



To a solution of 4-(piperidin-4-yl)phenol, HCl (0.026 g, 0.123 mmol) in Acetonitrile (3mL) was added DIPEA (0.065 mL, 0.370 mmol) followed by 4-10 bromo-2-(4-methylbenzyl)-1,2-oxazinan-3-one (0.035 g, 0.123 mmol). The mixture was then stirred at 80 °C for 16 h. The mixture was allowed to cool to RT and then concentrated. The crude material was purified via preparative LC/MS with the following conditions: Waters Xbridge C18, 19x150mm, 5µm; Guard Column: Waters XBridge C18, 19x10mm, 5µm; Mobile Phase A: 5:95 Acetonitrile:water with 15 0.1%TFA; Mobile Phase B: 95:5 Acetonitrile:water with 0.1%TFA; Gradient: 10-50% B over 25 minutes, followed by a 10 minute hold at 50% B and 5 minute hold at 100% B; Flow: 15ml/min. Fractions containing the desired product were combined and dried using a Genevac centrifugal evaporator to obtained **4** 4-(4-(4-hydroxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (6mg, 0.015 20 mmol, 12.55 % yield) as pale yellow solid. The racemic mixture was separated by Chiral HPLC/SFC to get **P1** and **P2**.

LCMS : A: 95% Water: 5% Acetonitrile; 10mM NH4OAC, B: 5% Water: 95% Acetonitrile; 10mM NH4OAC, Flow: 1.1 ml/min, Temp : 50°C, Column: Ascentis 25 Express C18 (50x2.1)mm, 2.7µm, Time (min) : 0---3, %B : 0---100, RT: 1.689min, (M+1) = 381.

1H NMR: 400 MHz, DMSO-d6: δ 1.93-1.99 (m, 4H), 2.21 (bs, 1H), 2.30 (s, 3H), 2.73-2.75 (m, 1H), 3.22-3.25 (m, 3H), 3.49-3.59 (m, 2H), 4.03 (bs, 1H), 4.24 (bs, 1H), 4.60 (bs, 1H), 4.72 (d, J = 15.20 Hz, 1H), 4.81 (d, J = 15.60 Hz, 1H), 6.73 (d, J = 8.00 Hz, 2H), 7.04 (d, J = 8.40 Hz, 2H), 7.17-7.23 (m, 4H), 9.26 (s, 1H).


Example 5 (P1 & P2):

To a solution of 4-((3S,4S)-3-fluoropiperidin-4-yl)phenol, HCl (0.05 g, 0.216 mmol) and DIPEA (0.113 mL, 0.647 mmol) in Acetonitrile (3 mL) was added 4-bromo-2-(4-methylbenzyl)-1,2-oxazinan-3-one (0.092 g, 0.324 mmol) and heated to 80 °C for overnight. The completion of the reaction was monitored by LCMS. Reaction mixture was concentrated under reduced pressure. The crude was purified by SCP obtained example 6 4-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (1.4mg, 3.44 µmol, 1.596 % yield) and remaining compound was separated by SFC obtained **P1** 4-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (5.5mg, 0.013 mmol, 6.08 % yield) and **P2** 4-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (2.7mg, 6.57 µmol, 3.05 % yield). The diasteromeric mixture was separated by Chiral HPLC/SFC to get **P1** and **P2**.

SFC Purification method:

Analytical SFC Conditions: Column/dimensions: Chiralpak OJ-H(250 X 4.6)mm,5u, % CO₂: 70%, % Co solvent: 30%(0.25% DEA in Methanol), Total Flow: 3.0g/min, Back Pressure: 100 bar, Temperature : 25°C, UV: 220.

Preparative SFC Conditions: Column/dimensions: Chiralpak OJ-H(250 X 21)mm,5u, % CO₂: 70%, % Co solvent: 30%(0.25% DEA in Methanol), Total Flow: 60.0g/min, Back Pressure: 100 bar, Temperature: 25°C, UV: 220, Peak number : Retention Time :: Peak 1 : 6.80 :: Peak 2 : 7.70
Solubility: Methanol 5ml, Loadability/Inj: 1.80mg/mL, Total No of injections:7, Total Time for purification0.3hrs, Instrument details: Make/Model: Thar SFC-80.


For P1 (homochiral):

5 **LCMS:** Column-Ascentis Express C18 (50X2.1mm-2.7 μ m), Mphase A : 10mM NH4C00H IN WATER:ACN(98:02), Mphase B : 10mM NH4C00H IN WATER:ACN(02:98), Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.7 : 100.0 :: 3.0 : 100.0 :: 3.2 : 0.0, RT-2.699min, (M+1) - 399.

10 **Chiral purity:** Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralcel OJ-H(4.6X250)mm,5u, Column Temperature : 23.5, Total Flow : 3, CO2 Flow Rate : 2.1, Co-Solvent Flow Rate : 0.9, Co-Solvent % : 30, Back Pressure : 100, RT - 6.66min.

15 **H-NMR :** 400 MHz, MeOD: δ 1.80-1.83 (m, 2H), 2.08-2.11 (m, 1H), 2.32 (s, 3H), 2.33-2.38 (m, 1H), 2.57-2.70 (m, 3H), 2.90-2.93 (m, 1H), 3.35-3.36 (m, 1H), 3.73 (t, J = 10.00 Hz, 1H), 3.97-4.07 (m, 2H), 4.53-4.70 (m, 2H), 4.77 (d, J = 14.80 Hz, 1H), 6.74 (dd, J = 8.80, Hz, 2H), 7.09 (dd, J = 8.80, Hz, 2H), 7.15 (d, J = 8.00 Hz, 2H), 7.23 (d, J = 8.00 Hz, 2H).

20

For P2 (homochiral):

25 **LCMS:** Column-Ascentis Express C18 (50X2.1mm-2.7 μ m), Mphase A : 10mM NH4C00H IN WATER:ACN(98:02), Mphase B : 10mM NH4C00H IN WATER:ACN(02:98), Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.7 : 100.0 :: 3.0 : 100.0 :: 3.2 : 0.0, RT-2.715min, (M+1)-399.


Chiral Purity: Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralcel OJ-H(4.6X250)mm,5u, Column Temperature : 23.5, Total Flow : 3, CO2 Flow Rate : 2.1, Co-Solvent Flow Rate: 0.9, Co-Solvent % : 30, Back Pressure : 100, RT-7.77 min.

5

H-NMR: 400 MHz, MeOD: δ 1.78-1.82 (m, 2H), 2.08-2.12 (m, 1H), 2.32 (s, 3H), 2.33-2.37 (m, 1H), 2.58-2.71 (m, 3H), 2.91-2.94 (m, 1H), 3.33-3.35 (m, 1H), 3.70-3.75 (m, 1H), 3.97-4.07 (m, 2H), 3.52-3.64 (m, 1H), 4.67 (d, J = 14.80 Hz, 1H), 4.76 (d, J = 14.80 Hz, 1H), 6.74 (dd, J = 8.40, Hz, 2H), 7.09 (dd, J = 8.40, Hz, 2H), 7.15 (d, J = 8.00 Hz, 2H), 7.22 (d, J = 8.00 Hz, 2H).

10

Example 6 (P1 and P2)



15 To a solution of 6-(piperidin-4-yl)pyridin-3-ol, HCl (0.05 g, 0.233 mmol) in Acetonitrile (3mL) was added DIPEA (0.122 mL, 0.699 mmol) followed by 4-bromo-2-(4-methylbenzyl)-1,2-oxazinan-3-one (0.132 g, 0.466 mmol). The mixture was then stirred at 80 °C for 16 h. The mixture was allowed to cool to RT and then concentrated to get crude 0.2g. The crude was purified by SCP. The crude material 20 was purified via preparative LC/MS with the following conditions: Waters Xbridge C18,19x150mm,5μm; Guard Column: Waters XBridge C18,19x10mm,5μm; Mobile Phase A:5:95 Acetonitrile:water with 10mM NH4OAc; Mobile Phase B: 95:5 Acetonitrile:water with 10mM NH4OAc; Gradient:10-40% B over 25minutes, followed by a 10 minute hold at 40% B and 5 minute hold at 100% 25 B; Flow:15ml/min. Fractions containing the desired product were combined and dried using a Genevac centrifugal evaporator to obtained example 7 4-(4-(5-hydroxypyridin-2-yl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (1.4mg, 3.67 μmol, 1.576 % yield). The racemic mixture was separated by Chiral HPLC/SFC to get **P1** and **P2**.

30 The racemic compound was separated by SFC obtained **P1** 4-(4-(5-hydroxypyridin-2-yl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (8.4mg, 0.022 mmol,

9.36 % yield) and **P2** 4-(4-(5-hydroxypyridin-2-yl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (8mg, 0.021 mmol, 8.91 % yield).

SFC condition:

Analytical SFC Conditions: Column/dimensions: Chiralcel OD-H(250 X


5 4.6)mm,5u, % CO2: 75%, % Co solvent: 25%(0.25% DEA in Methanol), Total Flow: 3.0g/min, Back Pressure: 100 bar, Temperature : 25°C, UV: 219.

Preparative SFC Conditions: Column/dimensions: Chiralcel OD-H(250 X

21)mm,5u% CO2: 75%, % Co solvent: 25%(0.25% DEA in Methanol), Total Flow: 60.0g/min, Back Pressure: 100 bar, Temperature: 25°C, UV: 219: Peak number :

10 Retention Time :: Peak 1 : 3.60 :: Peak 2 : 4.50, Solubility: Methanol in 10.0ml, Loadability/Inj: 5.0mg/mL, Total No of injections:10, Total Time for purification1.0hr, Instrument details: Make/Model: Thar SFC-80.


For P1 (homochiral):



15 **LCMS:** Column-Ascentis Express C8 (50X2.1mm-2.7μm), Mphase A : 2%ACN - 98 %H2O-10mM NH4C00H, Mphase B : 98%ACN - 2 %H2O-10mM NH4C00H, Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.5 : 100.0 :: 3.2 : 100.0, RT-1.782min, (M+1)-382.

Chiral SFC: Injection Volume : 10 , Co-Solvent : 0.3% DEA in Methanol, 20 Column : Chiralcel OD-H(4.6X250)mm,5u, Column Temperature : 23.5, Total Flow : 3, CO2 Flow Rate : 2.25 , Co-Solvent Flow Rate : 0.75, Co-Solvent % : 25, Back Pressure : 104, RT-4.04 min.

H-NMR : 400 MHz, MeOD: δ 1.81-1.91 (m, 4H), 2.10-2.14 (m, 1H), 2.34 (s, 3H), 25 1.36-2.41 (m, 1H), 2.62-2.70 (m, 2H), 2.80 (td, J = 22.40, Hz, 1H), 3.09 (s, 2H), 3.65-3.70 (m, 1H), 3.99-4.07 (m, 2H), 4.69 (d, J = 14.80 Hz, 1H), 4.78 (d, J = 14.80 Hz, 1H), 7.16-7.18 (m, 4H), 7.25 (d, J = 8.00 Hz, 2H), 7.98-7.99 (m, 1H).

For P2 (homochiral):

LCMS: Column-Ascentis Express C8 (50X2.1mm-2.7 μ m),Mphase A : 2%ACN - 98 %H2O-10mM NH4C00H, Mphase B : 98%ACN - 2 %H2O-10mM NH4C00H, Flow 5 = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.5 : 100.0 :: 3.2 : 100.0 :: RT - 1.798min, (M+1)-382.


Chiral SFC: Injection Volume : 10 , Co-Solvent : 0.3% DEA in Methanol, Column : Chiralcel OD-H(4.6X250)mm,5u, Column Temperature : 23.5, Total Flow : 3, CO2 Flow Rate : 2.25 , Co-Solvent Flow Rate : 0.75, Co-Solvent % : 25, 10 Back Pressure : 98, RT- 4.43 min.

H-NMR: 400 MHz, MeOD: δ 1.81-1.91 (m, 4H), 2.10-2.14 (m, 1H), 2.34 (s, 3H), 1.36-2.41 (m, 1H), 2.62-2.70 (m, 2H), 2.80 (td, J = 22.40, Hz, 1H), 3.09 (s, 2H), 3.65-3.70 (m, 1H), 3.99-4.07 (m, 2H), 4.69 (d, J = 14.80 Hz, 1H), 4.78 (d, J = 14.80 Hz, 1H), 7.16-7.20 (m, 4H), 7.25 (d, J = 8.00 Hz, 2H), 8.00-8.01 (m, 1H).

Example 7 (P1 & P2):

(3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one

20



To a solution of 4-((3R,4R)-3-fluoropiperidin-4-yl)phenol, HCl (0.05 g, 0.216 mmol) in Acetonitrile (3 mL) was added DIPEA (0.113 mL, 0.647 mmol) followed 25 by 4-bromo-2-(4-methylbenzyl)-1,2-oxazinan-3-one (0.123 g, 0.432 mmol). The mixture was then stirred at 80 °C for 16 h. The mixture was allowed to cool to RT and then concentrated. The residue was purified by SCP. The crude material was purified via preparative LC/MS with the following conditions: Waters Xbridge

C18,19x150mm,5 μ m; Guard Column: Waters XBridge C18,19x10mm,5 μ m; Mobile Phase A: 5:95 Acetonitrile:water with 10mM NH4OAc; Mobile Phase B: 95:5 Acetonitrile:water with 10mM NH4OAc; Gradient: 10-40% B over 25 minutes, followed by a 10 minute hold at 40% B and 5 minute hold at 100%

5 B; Flow: 15ml/min. Fractions containing the desired product were combined and dried using a Genevac centrifugal evaporator obtained example **8** 4-((3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (1.4mg, 3.51 μ mol, 1.628 % yield). The Diasteromeric mixture was separated by Chiral HPLC/SFC to get **P1** and **P2**.


10 The compound was separated by SFC obtained **P1** 4-((3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (14.1mg, 0.035 mmol, 16.23 % yield) and **P2** 4-((3R,4R)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (12.9mg, 15 0.032 mmol, 14.85 % yield).

SFC condition:

Analytical SFC Conditions: Column/dimensions: Chiralcel OD-H(250 X 4.6)mm,5u, % CO2: 75%, % Co solvent: 25%(0.25% DEA in Methanol), Total Flow: 3.0g/min, Back Pressure: 100 bar, Temperature : 25°C UV: 219.

20 **Preparative SFC Conditions:** Column/dimensions: Chiralcel OD-H(250 X 21)mm,5u, % CO2: 75%, % Co solvent: 25%(0.25% DEA in Methanol), Total Flow: 60.0g/min, Back Pressure: 100 bar, Temperature: 25°C, UV: 219, Peak number : Retention Time :: Peak 1 : 6.50 :: Peak 2 : 8.50, Solubility: Methanol in 10.0ml, Loadability/Inj: 5.0mg/mL, Total No of injections:10, Total Time for 25 purification1.0hr, Instrument details: Make/Model: Thar SFC-80.

For P1 (homochiral):



LCMS : Column-Ascentis Express C8 (50X2.1mm-2.7 μ m), Mphase A : 2%ACN - 30 98 %H2O-10mM NH4C00H Mphase B : 98%ACN - 2 %H2O-10mM NH4C00H,


Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.5 : 100.0 :: 3.2 : 100.0, RT - 1.96min, (M+1)- 399.

5 **H-NMR:** 400 MHz, MeOD: δ 1.80-1.85 (m, 2H), 2.09-2.15 (m, 1H), 2.35 (s, 3H), 2.36-2.41 (m, 1H), 2.55-2.67 (m, 2H), 2.72-2.79 (m, 1H), 2.95-2.98 (m, 1H), 3.35-3.37 (m, 1H), 3.73-3.77 (m, 1H), 3.99-4.02 (m, 1H), 4.05-4.10 (m, 1H), 4.53-4.67 (m, 1H), 4.70 (d, J = 14.80 Hz, 1H), 4.79 (d, J = 14.80 Hz, 1H), 6.76 (dt, J = 14.40, Hz, 2H), 7.12 (dt, J = 14.00, Hz, 2H), 7.17 (d, J = 8.00 Hz, 2H), 7.25 (d, J = 8.00 Hz, 2H).

10 **Chiral SFC:** Injection Volume: 10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralcel OD-H(4.6X250)mm, 5u, Column Temperature : 23.6, Total Flow : 3, CO2 Flow Rate : 2.25, Co-Solvent Flow Rate: 0.75, Co-Solvent % : 25, Back Pressure : 103, RT - 5.88min.

For P2 (homochiral):

15



LCMS: Column-Ascentis Express C8 (50X2.1mm-2.7 μ m), Mphase A : 2%ACN - 98 %H2O-10mM NH4C00HMphase B : 98%ACN - 2 %H2O-10mM NH4C00H, Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.5 : 100.0 :: 3.2 : 100.0, RT-1.965min, (M+1):399.


20 **H-NMR :** 400 MHz, MeOD: δ 1.81-1.86 (m, 2H), 2.07-2.13 (m, 1H), 2.35 (s, 3H), 2.36-2.41 (m, 1H), 2.54-2.74 (m, 3H), 2.93-2.96 (m, 1H), 3.36-3.37 (m, 1H), 3.74-3.78 (m, 1H), 3.99-4.03 (m, 1H), 4.05-4.10 (m, 1H), 4.54-4.67 (m, 1H), 4.70 (d, J = 14.80 Hz, 1H), 4.79 (d, J = 15.20 Hz, 1H), 6.76 (dt, J = 11.20, Hz, 2H), 7.11 (dt, J = 11.20, Hz, 2H), 7.18 (d, J = 8.00 Hz, 2H), 7.25 (d, J = 8.00 Hz, 2H).

25 **Chiral SFC:** Injection Volume: 10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralcel OD-H(4.6X250)mm, 5u, Column Temperature : 23.6, Total Flow : 3, CO2 Flow Rate : 2.25, Co-Solvent Flow Rate: 0.75, Co-Solvent % : 25, Back Pressure : 105, RT – 6.77min.

30

Example 8 (P1 & P2):

5 **4-(4-(5-hydroxypyridin-2-yl)piperazin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one**



To a solution of 6-(piperazin-1-yl)pyridin-3-ol, HCl (0.05 g, 0.232 mmol) in Acetonitrile (3mL) was added DIPEA (0.243 mL, 1.394 mmol) followed by 4-bromo-2-(4-methylbenzyl)-1,2-oxazinan-3-one (0.132 g, 0.465 mmol). The mixture was then stirred at 80 °C for 16 h. The mixture was allowed to cool to RT and then concentrated. The residue was purified by SCP. The crude material was purified via preparative LC/MS with the following conditions: Waters Xbridge C18,19x150mm,5μm; Guard Column: Waters XBridge C18,19x10mm,5μm; Mobile Phase A:5:95 Acetonitrile:water with 10mM NH4OAc; Mobile Phase B: 95:5 Acetonitrile:water with 10mM NH4OAc; Gradient: 10-40% B over 25minutes, followed by a 10 minute hold at 40% B and 5 minute hold at 100% B; Flow: 15ml/min. Fractions containing the desired product were combined and dried using a Genevac centrifugal evaporator obtained example 8 4-(4-(5-hydroxypyridin-2-yl)piperazin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one. The racemic mixture 8 was separated by Chiral HPLC/SFC to get **P1** and **P2**. The compound **8** was separated obtained **P1** 4-(4-(5-hydroxypyridin-2-yl)piperazin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (5.7mg, 0.014 mmol, 3.08 % yield) and **P2** 4-(4-(5-hydroxypyridin-2-yl)piperazin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (4.9 mg, 0.012 mmol, 2.68 % yield).


SFC Purification condition:

Analytical SFC Conditions: Column/dimensions: Chiralcel OD-H(250 X 4.6)mm,5u, % CO2: 60%, % Co solvent: 40%(0.25% DEA in Methanol), Total Flow: 4.0g/min, Back Pressure: 100 bar, Temperature : 25°C UV: 246.

30 **Preparative SFC Conditions:** Column/dimensions: Chiralcel OD-H(250 X 21)mm,5u, % CO2: 60%, % Co solvent: 40%(0.25% DEA in Methanol), Total Flow:

60.0g/min, Back Pressure: 100 bar, Temperature: 25°C, UV: 246, Peak number :
 Retention Time :: Peak 1 : 4.00 :: Peak 2 : 5.00, Solubility: Methanol in 5.0ml,
 Loadability/Inj: 4.0mg/mL, Total No of injections:5, Total Time for
 purification1.0hr, Instrument details: Make/Model: Thar SFC-80.

5 **For P1 (homochiral):**




LCMS: Column-Ascentis Express C18 (50X2.1mm-2.7μm), Mphase A : 10mM Ammonium Acetate in water, Mphase B : CAN, Flow = 1ML/MIN, Time: % A : %B :: 0.0 : 100.0 : 0.0 :: 1.7 : 0.0 : 100.0 :: 3.2 : 0.0 :100.0, RT-2.007min;(M+1):383.

10 **1H-NMR:** 400 MHz, MeOD: δ 2.04-2.10 (m, 1H), 2.32 (s, 3H), 2.34-2.41 (m, 1H), 2.84-2.89 (m, 2H), 2.91-2.96 (m, 2H), 3.37 (t, J = 10.00 Hz, 4H), 3.64-3.69 (m, 1H), 3.95-3.99 (m, 1H), 4.02-4.06 (m, 1H), 4.66 (d, J = 15.20 Hz, 1H), 4.77 (d, J = 15.20 Hz, 1H), 6.76 (d, J = 9.20 Hz, 1H), 7.12-7.16 (m, 3H), 7.20-7.23 (m, 2H), 7.73 (d, J = 3.20 Hz, 1H).

15 **Chiral SFC:** Injection Volume: 10, Co-Solvent: 0.3% DEA in Methanol, Column : Chiralcel OD-H(4.6X250)mm,5u, Column Temperature: 24.5, Total Flow : 4, CO2 Flow Rate : 2.4,
 Co-Solvent Flow Rate: 1.6, Co-Solvent % : 40, Back Pressure : 74, RT -2.81min.

20 **For P2 (homochiral):**




LCMS: Column-Ascentis Express C18 (50X2.1mm-2.7μm), Mphase A : 10mM Ammonium Acetate in water, Mphase B : CAN, Flow = 1ML/MIN, Time : % A : %B :: 0.0 : 100.0 : 0.0 :: 1.7 : 0.0 : 100.0 :: 3.2 : 0.0 :100.0, RT-

25 2.005min;(M+1):383.
1H-NMR: 400 MHz, MeOD: δ 2.04-2.10 (m, 1H), 2.32 (s, 3H), 2.34-2.41 (m, 1H), 2.84-2.89 (m, 2H), 2.91-2.96 (m, 2H), 3.37 (t, J = 10.00 Hz, 4H), 3.64-3.69 (m, 1H), 3.95-3.99 (m, 1H), 4.02-4.06 (m, 1H), 4.66 (d, J = 15.20 Hz, 1H), 4.77 (d, J = 15.20

Hz, 1H), 6.76 (d, J = 9.20 Hz, 1H), 7.12-7.16 (m, 3H), 7.20-7.23 (m, 2H), 7.73 (d, J = 3.20 Hz, 1H).

Chiral SFC: Injection Volume: 10, Co-Solvent: 0.3% DEA in Methanol, Column : Chiralcel OD-H(4.6X250)mm,5u, Column Temperature: 24.5, Total Flow : 4, CO2 Flow Rate : 2.4, Co-Solvent Flow Rate: 1.6, Co-Solvent % : 40, Back Pressure : 74, RT – 3.68min.

Example 9 (P1 & P2):



10


4-bromo-2-(4-methylbenzyl)isoxazolidin-3-one (0.094 g, 0.349 mmol) in ACN (5 mL) was added DIPEA (0.122 mL, 0.699 mmol) and 6-(piperidin-4-yl)pyridin-3-ol, HCl (0.05 g, 0.233 mmol) at RT. The reaction mixture was stirred at 60 °C for 18 h. 13% Desired product mass by LCMS. The reaction mixture was concentrated and 15 was submitted to SCP. The compound was purified by SCP to get racemic mixture **10**, 4-(4-(5-hydroxypyridin-2-yl)piperidin-1-yl)-2-(4-methylbenzyl)isoxazolidin-3-one (13 mg, 0.035 mmol, 14.89 % yield) and was racemic mixture was separated by Chiral SFC to get **P1** 4-(4-(5-hydroxypyridin-2-yl)piperidin-1-yl)-2-(4-methylbenzyl)isoxazolidin-3-one (1.6 mg, 4.18 μmol, 1.795 % yield) and **P2** 4-(4-(5-20 hydroxypyridin-2-yl)piperidin-1-yl)-2-(4-methylbenzyl)isoxazolidin-3-one (2.7 mg, 6.83 μmol, 2.93 % yield).

SFC Purification method

25 **Analytical SFC Conditions:** Column/dimensions: Lux Amylose-2(250 X 4.6)mm,5u, % CO2: 60%, % Co solvent: 40%(0.25% DEA in Methanol), Total Flow: 3.0g/min, Back Pressure: 100 bar, Temperature : 25°C, UV: 220.

Preparative SFC Conditions: Column/dimensions: Lux Amylose-2(250 X 21.5)mm,5u, % CO₂: 60%, % Co solvent: 40%(0.25% DEA in Methanol), Total Flow: 60.0g/min, Back Pressure: 100 bar, Temperature: 25°C, UV: 220, Peak number : Retention Time :: Peak 1 : 3.50 :: Peak 2 5.10 :: Solubility: Methanol in 5 10.0ml, Loadability/Inj: 3.0mg/mL, Total No of injections:09, Total Time for purification1.00hr, Instrument details: Make/Model: Thar SFC-80.

For P1 (homochiral):



10

LCMS: Column-Ascentis Express C18 (50X2.1mm-2.7μm), Mphase A : 10mM NH₄C00H IN WATER:ACN(98:02), Mphase B : 10mM NH₄C00H IN WATER:ACN(02:98), Flow = 1ML/MIN, Time : %B : 0.0 : 0.0 :: 1.7 : 100.0 :: 3.0 : 100.0 :: 3.2 : 0.0, RT-2.019min, M(+1)-368.

15


Chiral purity: Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column: Lux amylose-2(250X4.6)mm 5u, Column Temperature : 22.1, Total Flow :3, CO₂ Flow Rate: 2.1, Co-Solvent Flow Rate : 0.9, Co-Solvent % : 30, Back Pressure : 103, RT- 4.46min.

20

1H NMR: 400 MHz, MeOD: δ 1.74-1.91 (m, 5H), 2.31 (s, 3H), 2.43 (t, J = 11.20 Hz, 1H), 2.62 (t, J = 16.00 Hz, 1H), 2.86-2.95 (m, 2H), 3.18-3.22 (m, 1H), 3.88-3.91 (m, 1H), 4.31-4.35 (m, 1H), 4.40-4.45 (m, 1H), 4.64-4.74 (m, 2H), 7.15-7.25 (m, 6H), 7.98-7.99 (m, 1H).

25

For P2(homochiral):




LCMS: Column-Ascentis Express C18 (50X2.1mm-2.7 μ m), Mphase A : 10mM NH4COOH IN WATER:ACN(98:02), Mphase B : 10mM NH4COOH IN WATER:ACN(02:98), Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.7 : 100.0 :: 3.0 : 100.0, 3.2 : 0.0, RT-2.021min, M(+1)-368.

5 **Chiral purity:** Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Lux amylose-2(250X4.6)mm 5u, Column Temperature : 22.1, Total Flow : 3, CO2 Flow Rate: 2.1, Co-Solvent Flow Rate: 0.9, Co-Solvent % : 30, Back Pressure : 102, RT-5.67min.

10 **1H NMR:** 400 MHz, MeOD: δ 1.74-1.91 (m, 4H), 2.31 (s, 3H), 2.43 (t, J = 11.20 Hz, 1H), 2.62 (t, J = 16.00 Hz, 1H), 2.86-2.95 (m, 2H), 3.18-3.22 (m, 1H), 3.88-3.91 (m, 1H), 4.31-4.35 (m, 1H), 4.40-4.45 (m, 1H), 4.64-4.74 (m, 2H), 7.15-7.25 (m, 6H), 7.98-7.99 (m, 1H).

15 **Example 10 (P1 and P2)**

4-(4-(5-hydroxypyridin-2-yl)piperazin-1-yl)-2-(4-methylbenzyl)isoxazolidin-3-one



20

To a solution 4-(4-(benzyloxy)pyridin-2-yl)piperazin-1-yl)-2-(4-methylbenzyl)isoxazolidin-3-one (0.2 g, 0.305 mmol) in MeOH (10 mL) was added Pd/C (0.2 g, 0.188 mmol) and stirred at RT under hydrogen balloon pressure for 16 h. The mixture was filtered through celite, the filterate was concentrated. The crude material was purified via preparative LC/MS with the following conditions: Waters Xbridge C18, 19x150mm, 5 μ m; Guard Column: Waters XBridge C18, 19x10mm, 5 μ m; Mobile Phase A: 5:95 Methanol:water with 10mM NH4OAc; Mobile Phase B: 95:5 Methanol:water with 10mM NH4OAc; Gradient: 15-60% B over 25 minutes, followed by a 10 minute hold at 60% B and 5 minute hold at 100% B; flow: 15ml/min. Fractions containing the desired product were combined and dried using a Genevac centrifugal evaporator obtained **12** 4-(4-(5-hydroxypyridin-2-yl)piperazin-1-yl)-2-

(4-methylbenzyl)isoxazolidin-3-one (1.5mg, 4.03 μ mol, 1.320 % yield). The racemic mixture was separated by Chiral HPLC/SFC to get **P1** and **P2**.

H-NMR: 400 MHz, DMSO-d6: δ 2.30 (s, 3H), 2.56-2.61 (m, 2H), 2.91-2.96 (m, 2H), 3.28 (t, J = 10.00 Hz, 4H), 3.82-3.85 (m, 1H), 4.23-4.27 (m, 1H), 4.36 (t, J = 17.60 Hz, 1H), 4.62 (s, 2H), 6.72 (d, J = 8.80 Hz, 1H), 7.06 (dd, J = 12.00, Hz, 1H), 7.15-7.20 (m, 4H), 7.74 (d, J = 2.80 Hz, 1H), 8.97 (s, 1H).

LCMS: A: 95% Water: 5% Acetonitrile; 10mM NH4OAC, B: 5% Water: 95% Acetonitrile; 10mM NH4OAC Flow: 1.1 ml/min, Temp: 50°C, Column: Ascentis Express C18 (50x2.1)mm, 2.7 μ m, Time (min): 0---3, %B: 0---100, RT: 1.229min, 10 (M+1)-369.

The compound **12** was separated by SFC obtained **P1** 4-(4-(5-hydroxypyridin-2-yl)piperazin-1-yl)-2-(4-methylbenzyl)isoxazolidin-3-one (4mg, 10.31 μ mol, 3.38 % yield) and **P2** 4-(4-(5-hydroxypyridin-2-yl)piperazin-1-yl)-2-(4-methylbenzyl)isoxazolidin-3-one (6mg, 0.015 mmol, 5.07 % yield).


15 **SFC Purification Method:**

Analytical SFC Conditions: Column/dimensions: Chiralpak OJ-H(250 X 4.6)mm, 5u, % CO2: 70%, % Co solvent: 30%(0.25% DEA in Methanol), Total Flow: 4.0g/min, Back Pressure: 100 bar, Temperature: 25°C, UV: 220.

Preparative SFC Conditions: Column/dimensions: Chiralpak OJ-H(250 X 21)mm, 5u, % CO2: 70%, % Co solvent: 30%(0.25% DEA in Methanol), Total Flow: 70.0g/min, Back Pressure: 100 bar, Temperature: 25°C, UV: 220, Peak number: Retention Time :: Peak 1: 4.20 :: Peak 2: 5.50 :: Solubility: 6ml in Methanol, Loadability/Inj: 3.5mg/mL, Total No of injections 15Total Time for purification 2hrs, Instrument details: Make/Model: Thar SFC-80.

25

For P1(homochiral):




LCMS: Column-Ascentis Express C18 (50X2.1mm-2.7 μ m), Mphase A: 10mM NH4C00H IN WATER:ACN(98:02), Mphase B: 10mM NH4C00H IN WATER:ACN(02:98), Flow = 1ML/MIN, Time: %B: 0.0: 0.0: 1.7: 100.0: 3.0: 100.0: 3.2: 0.0, RT -2.209min, (M+1)-369.

1H-NMR : 400 MHz, DMSO-d6: δ 2.29 (s, 3H), 2.56-2.59 (m, 2H), 2.91-2.94 (m, 2H), 3.27 (t, J = 10.00 Hz, 4H), 3.81-3.84 (m, 1H), 4.22-4.26 (m, 1H), 4.35 (t, J = 20.40 Hz, 1H), 4.61 (s, 2H), 6.71 (d, J = 8.80 Hz, 1H), 7.05 (dd, J = 12.40, Hz, 1H), 7.16-7.20 (m, 4H), 7.73 (d, J = 2.80 Hz, 1H), 8.96 (s, 1H).

5 **Chiral SFC:** Injection Volume : 9, Co-Solvent : 0.3% DEA in Methanol , Column : Chiralcel OJ-H(4.6X250)mm,5u, Column Temperature : 23.9, Total Flow : 4, CO2 Flow Rate : 2.8, Co-Solvent Flow Rate : 1.2, Co-Solvent % : 30, Back Pressure : 100, RT - 3.67min.

10 **For P2 (homochiral):**




LCMS: Column-Ascentis Express C18 (50X2.1mm-2.7 μ m), Mphase A : 10mM NH4C00H IN , WATER:ACN(98:02), Mphase B : 10mM NH4C00H IN WATER:ACN(02:98), Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.7 : 100.0 :: 3.0 : 15 100.0 :: 3.2 : 0.0, RT-2.207min;(M+1):369.

15 **H-NMR:** 400 MHz, DMSO-d6: δ 2.29 (s, 3H), 2.56-2.59 (m, 2H), 2.91-2.94 (m, 2H), 3.27 (t, J = 10.00 Hz, 4H), 3.81-3.84 (m, 1H), 4.22-4.26 (m, 1H), 4.35 (t, J = 20.40 Hz, 1H), 4.61 (s, 2H), 6.71 (d, J = 8.80 Hz, 1H), 7.05 (dd, J = 12.40, Hz, 1H), 7.16-7.20 (m, 4H), 7.73 (d, J = 2.80 Hz, 1H), 8.96 (s, 1H).

20 **Chiral SFC:** Injection Volume : 9, Co-Solvent : 0.3% DEA in Methanol , Column : Chiralcel OJ-H(4.6X250)mm,5u, Column Temperature : 23.9, Total Flow : 4, CO2 Flow Rate : 2.8, Co-Solvent Flow Rate : 1.2, Co-Solvent % : 30, Back Pressure : 100, RT – 4.63min.

25 **Example 11 (P1 and P2)**

4-(3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one




To a solution 2-fluoro-4-(3-fluoropiperidin-4-yl)phenol (0.1 g, 0.469 mmol) in DMF (3 mL) was added DIPEA (0.246 mL, 1.407 mmol) followed by 4-bromo-2-(4-methylbenzyl)-1,2-oxazinan-3-one (0.200 g, 0.703 mmol) then heated to 120 °C
5 for 90 minutes in microwave. The mixture was allowed to cool to RT and then concentrated. The crude material was purified via preparative LC/MS with the following conditions: Waters Xbridge C18,19x150mm,5μm; Guard Column: Waters XBridge C18,19x10mm,5μm; Mobile Phase A:5:95 Acetonitrile:water with 10mM NH4OAc; Mobile Phase B: 95:5 Acetonitrile: water with 10mM NH4OAc;
10 Gradient:15-50% B over 25minutes, followed by a 10 minute hold at 50% B and 5 minute hold at 100% B;Flow:15ml/min. Fractions containing the desired product were combined and dried using a Genevac centrifugal evaporator to obtain **11** 4-(3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (26mg, 0.062 mmol, 13.31 % yield). The diasteromeric mixture was
15 separated by Chiral HPLC/SFC to get **P1** and **P2**.

SFC purification condition:

Analytical SFC Conditions: Column/dimensions: Luxcellulose-2(250 X 4.6)mm,5u, % CO2: 60%, % Co solvent: 40%(0.25% DEA in Methanol), Total Flow: 4.0g/min,
20 Back Pressure: 100 bar, Temperature : 25°C, UV: 220.

Preparative SFC Conditions: Column/dimensions: Luxcellulose-2(250 X 21.5)mm,5u, % CO2: 60%, % Co solvent: 40%(0.25% DEA in Methanol), Total Flow: 75g/min, Back Pressure: 100 bar, Temperature: 25°C UV: 220, Peak number :
Retention Time :: Peak 1 : 3.50 :: Peak 2 : 4.10, *Solubility*: 10ml in Methanol,
25 Loadability/Inj: 3mg/mL, Total No of injections 08, Total Time for purification 30min. *Instrument details*: Make/Model: Thar SFC-80.


The compound **11** was separated by SFC to get **P1** ; 4-(3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (8mg, 0.019 mmol, 4.05 % yield) and **P2**, 4-(3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl)-2-(4-methylbenzyl)-1,2-oxazinan-3-one (9mg, 0.021 mmol, 4.56 % yield).

For P1(homochiral):

LCMS: Column-Ascentis Express C18 (50X2.1mm-2.7μm), Mphase A : 10mM NH4C00H IN WATER:ACN(98:02), Mphase B : 10mM NH4C00H IN WATER:ACN(02:98), Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.5 : 100.0 :: 3.2 : 100.0, RT-2.658min;(M+1)-417.

H-NMR: 400 MHz, CDCl₃: δ 1.78-1.87 (m, 2H), 2.04-2.10 (m, 1H), 2.30-2.35 (m, 4H), 2.59-2.64 (m, 1H), 2.73 (td, J = 24.80, Hz, 1H), 2.86 (td, J = 22.40, Hz, 1H), 2.99-3.01 (m, 1H), 3.31-3.33 (m, 1H), 3.65-3.70 (m, 1H), 3.93-3.97 (m, 1H), 3.99-4.04 (m, 1H), 4.50-4.63 (m, 1H), 4.72 (s, 2H), 6.94-6.96 (m, 2H), 7.01 (dd, J = 12.00, Hz, 1H), 7.14 (d, J = 7.60 Hz, 2H), 7.24 (d, J = 8.00 Hz, 2H).

Chiral SFC: Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Lux cellulose-2(4.6X250)mm,5u, Column Temperature : 24.9, Total Flow : 4, CO₂ Flow Rate : 2.4, Co-Solvent Flow Rate : 1.6, Co-Solvent % : 40, Back Pressure : 101, RT-2.83min.

For P2(homochiral):

LCMS: Column-Ascentis Express C18 (50X2.1mm-2.7μm), Mphase A : 10mM NH4C00H IN WATER:ACN(98:02), Mphase B : 10mM NH4C00H IN WATER:ACN(02:98), Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.5 : 100.0 :: 3.2 : 100.0, RT - 2.64min, (M+1)-417.


H-NMR: 400 MHz, CDCl₃: δ 1.78-1.88 (m, 2H), 2.05-2.08 (m, 1H), 2.31-2.35 (m, 4H), 2.60-2.69 (m, 2H), 2.81 (td, J = 19.60, Hz, 1H), 2.91-2.94 (m, 1H), 3.41-3.44 (m, 1H), 3.64-3.71 (m, 1H), 3.93-3.97 (m, 1H), 3.99-4.04 (m, 1H), 4.53-4.67 (m, 1H), 4.72 (d, J = 5.60 Hz, 2H), 6.92-6.96 (m, 2H), 6.98-7.02 (m, 1H), 7.14 (d, J = 8.00 Hz, 2H), 7.24 (d, J = 8.00 Hz, 2H).

Chiral SFC: Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Lux cellulose-2(4.6X250)mm,5u, Column Temperature : 24.9, Total Flow : 4, CO2 Flow Rate : 2.4, Co-Solvent Flow Rate : 1.6, Co-Solvent % : 40, Back Pressure : 101, RT- 3.33min.

5

Example 12 (P1 & P2)

2-(4-chlorobenzyl)-4-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1,2-oxazinan-3-one



10

To a solution 4-((3S,4S)-3-fluoropiperidin-4-yl)phenol (0.1 g, 0.512 mmol) in DMF (2 mL) was added DIPEA (0.268 mL, 1.537 mmol) followed by 4-bromo-2-(4-chlorobenzyl)-1,2-oxazinan-3-one (0.234 g, 0.768 mmol) then heated to 120 °C for 90 minutes in microwave. The mixture was allowed to cool to RT and then concentrated. The crude material was purified via preparative LC/MS with the following conditions: Waters Xbridge C18, 19x150mm, 5µm; Guard Column: Waters XBridge C18, 19x10mm, 5µm; Mobile Phase A: 5:95 Acetonitrile:water with 10mM NH4OAc; Mobile Phase B: 95:5 Acetonitrile:water with 10mM NH4OAc; Gradient: 15-50% B over 25 minutes, followed by a 10 minute hold at 50% B and 5 minute hold at 100% B; Flow: 15ml/min. Fractions containing the desired product were combined and dried using a Genevac centrifugal evaporator to get **12** 2-(4-chlorobenzyl)-4-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1,2-oxazinan-3-one (53mg, 0.125 mmol, 24.45 % yield). The diasteromeric mixture was separated by Chiral HPLC/SFC to get **P1** and **P2**.

15 **SFC Purification condition:**

Analytical SFC Conditions: Column/dimensions: Luxcellulose-2(250 X 4.6)mm, 5u, % CO2: 60%, % Co solvent: 40%(0.25% DEA in Methanol), Total Flow: 4.0g/min, Back Pressure: 100 bar, Temperature : 25°C, UV: 222.


20 **Preparative SFC Conditions :** Column/dimensions: Luxcellulose-2(250 X 21.5)mm, 5u, % CO2: 60%, % Co solvent: 45%(0.25% DEA in Methanol), Total

Flow: 75g/min, Back Pressure: 100 bar, Temperature: 25°C, UV: 222, Peak number :
 Retention Time :: Peak 1: 3.90 :: Peak 2 : 4.80 :: Solubility: 10ml in Methanol,
 Loadability/Inj: 5mg/mL, Total No of injections 10 Total Time for purification 45min,
 Instrument details: Make/Model: Thar SFC-80.

5 The compound **14** was separated by SFC obtained **P1** 2-(4-chlorobenzyl)-4-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1,2-oxazinan-3-one (17mg, 0.040 mmol, 7.84 % yield) and **P2** 2-(4-chlorobenzyl)-4-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1,2-oxazinan-3-one (15mg, 0.035 mmol, 6.92 % yield) as off white solid.

10

For P1(homochiral):




LCMS: Column-Ascentis Express C18 (50X2.1mm-2.7μm): Mphase A : 10mM NH4C00H IN WATER:ACN(98:02), Mphase B : 10mM NH4C00H IN WATER:ACN(02:98), Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.7 : 100.0 :: 3.0 : 100.0 :: 3.2 : 0.0, RT -2.766min, M(+1) -419.

15 **H-NMR** : 400 MHz, CDCl3: δ 1.84-1.87 (m, 2H), 2.06-2.12 (m, 1H), 2.32-2.36 (m, 1H), 2.61-2.74 (m, 2H), 2.84 (dt, J = 25.60, Hz, 1H), 2.98-3.00 (m, 1H), 3.30-3.32 (m, 1H), 3.66-3.70 (m, 1H), 3.97-4.05 (m, 2H), 4.53-4.68 (m, 1H), 4.72 (s, 2H), 6.80 (d, J = 8.40 Hz, 2H), 7.14 (d, J = 8.80 Hz, 2H), 7.27-7.33 (m, 4H).

20 **Chiral SFC:** Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Lux cellulose-2(4.6X250)mm,5u, Column Temperature : 24.7, Total Flow : 4, CO2 Flow Rate : 2.4, Co-Solvent Flow Rate : 1.6, Co-Solvent % : 40, Back Pressure : 101, RT- 3.7min.

25 **For P2 (homochiral):**




LCMS: Column-Ascentis Express C18 (50X2.1mm-2.7 μ m), Mphase A : 10mM NH4C00H IN WATER:ACN(98:02), Mphase B : 10mM NH4C00H IN WATER:ACN(02:98), Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.7 : 100.0 :: 3.0 : 100.0 :: 3.2 : 0.0, RT - 2.762min, (M+1) – 419.

5 **H-NMR:** 400 MHz, CDCl₃: δ 1.85-1.88 (m, 2H), 2.04-2.10 (m, 1H), 2.32-2.37 (m, 1H), 2.64 (dt, J = 26.40, Hz, 2H), 2.79 (dt, J = 24.40, Hz, 2H), 2.92 (d, J = 10.80 Hz, 1H), 3.40-3.43 (m, 1H), 3.64-3.69 (m, 1H), 3.95-4.06 (m, 2H), 4.56-4.68 (m, 1H), 4.69 (s, 2H), 6.80 (d, J = 8.40 Hz, 2H), 7.14 (d, J = 8.80 Hz, 2H), 7.27-7.33 (m, 4H).

10 **Chiral SFC:** Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Lux cellulose-2(4.6X250)mm,5u, Column Temperature : 24.7, Total Flow : 4, CO₂ Flow Rate : 2.4, Co-Solvent Flow Rate : 1.6, Co-Solvent % : 40, Back Pressure : 101, RT- 4.57min.

Example 13 (P1 & P2)

15 **4-(3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl)-2-(4-fluorobenzyl)-1,2-oxazinan-3-one**



20 To a solution of 2-fluoro-4-(3-fluoropiperidin-4-yl)phenol (0.1 g, 0.469 mmol) in DMF (2 mL) was added DIPEA (0.246 mL, 1.407 mmol) followed by 4-bromo-2-(4-fluorobenzyl)-1,2-oxazinan-3-one (0.203 g, 0.703 mmol) then heated to 120 °C for 90 minutes in microwave. The mixture was allowed to cool to RT and then concentrated. The crude material was purified via preparative LC/MS with the following conditions: Waters Xbridge C18, 19x150mm, 5 μ m; Guard Column: Waters XBridge C18, 19x10mm, 5 μ m; Mobile Phase A: 5:95 Acetonitrile:water with 10mM NH4OAc; Mobile Phase B: 95:5 Acetonitrile:water with 10mM NH4OAc; Gradient: 15-50% B over 25 minutes, followed by a 10 minute hold at 50% B and 5 minute hold at 100% B; Flow: 15ml/min. Fractions containing the desired product were combined and dried using a Genevac centrifugal evaporator to obtain **13** 4-(3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl)-2-(4-fluorobenzyl)-1,2-oxazinan-

25

30

3-one (23mg, 0.054 mmol, 11.43 % yield). The diasteromeric mixture was separated by Chiral HPLC/SFC to get **P1** and **P2**.

SFC Purification method:

Analytical SFC Conditions: Column/dimensions: Chiralpak AD-H(250 X

5 4.6)mm,5u, % CO2: 60%, % Co solvent: 40%(0.25% DEA in Methanol), Total Flow: 4.0g/min., Back Pressure: 100 bar, Temperature : 25°C, UV: 220.

Preparative SFC Conditions: Column/dimensions: Chiralpak AD-H(250 X


21)mm,5u, % CO2: 60%, % Co solvent: 45%(0.25% DEA in Methanol), Total Flow: 75g/min, Back Pressure: 100 bar, Temperature: 25°C, UV: 220, Peak number :

10 Retention Time :: Peak 1 : 4.60 :: Peak 2 : 6.00. Solubility: 10ml in Methanol, Loadability/Inj: 2mg/mL, Total No of injections 09 Total Time for purification 1hrs, Instrument details: Make/Model: Thar SFC-80.

The compound **15** was separated by SFC obtained **P1** 4-(3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl)-2-(4-fluorobenzyl)-1,2-oxazinan-3-one (6mg, 0.014

15 mmol, 3.01 % yield) and **P2** 4-(3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl)-2-(4-fluorobenzyl)-1,2-oxazinan-3-one (6mg, 0.014 mmol, 3.01 % yield) as off white solid.

For P1(homochiral):



20 **LCMS :** Column-Ascentis Express C18 (50X2.1mm-2.7μm), Mphase A : 10mM NH4C00H IN WATER:ACN(98:02), Mphase B : 10mM NH4C00H IN WATER:ACN(02:98), Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.7 : 100.0 :: 3.0 : 100.0 :: 3.2 : 0.0, RT - 2.697min, (M(+1) – 421.


25 **H-NMR:** 400 MHz, CDCl3: δ 1.78-1.88 (m, 2H), 2.03-2.09 (m, 1H), 2.32-2.36 (m, 1H), 2.60-2.68 (m, 2H), 2.81 (dt, J = 24.40, Hz, 1H), 2.90-2.94 (m, 1H), 3.40-3.43 (m, 1H), 3.63-3.68 (m, 1H), 3.93-4.05 (m, 2H), 4.51-4.65 (m, 1H), 4.66 (s, 2H), 6.94-7.04 (m, 5H), 7.31-7.34 (m, 2H).

Chiral SFC: Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralpak AD H (250 X 4.6)mm 5u, Column Temperature : 24.6, Total Flow : 4,

30 CO2 Flow Rate : 2.4, Co-Solvent Flow Rate : 1.6, Co-Solvent % : 40, Back

Pressure : 99, RT- 4.37min.

For P2(homochiral):




LCMS: Column-Ascentis Express C18 (50X2.1mm-2.7 μ m), Mphase A : 10mM NH4C00H IN WATER:ACN(98:02), Mphase B : 10mM NH4C00H IN WATER:ACN(02:98), Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.7 : 100.0 :: 3.0 : 100.0 :: 3.2 : 0.0, RT - 2.702min;(M+1) – 421.

H-NMR: 400 MHz, CDCl₃: δ 1.78-1.88 (m, 2H), 2.05-2.11 (m, 1H), 2.31-2.36 (m, 1H), 2.63 (dt, J = 22.40, Hz, 1H), 2.72 (dt, J = 24.80, Hz, 1H), 2.86 (dt, J = 25.60, Hz, 1H), 2.98-3.00 (m, 1H), 3.30-3.32 (m, 1H), 3.65-3.69 (m, 1H), 3.95-4.05 (m, 2H), 4.49-4.62 (m, 1H), 4.71 (s, 2H), 6.94-7.05 (m, 5H), 7.31-7.34 (m, 2H).

Chiral SFC: Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralpak AD H (250 X 4.6)mm 5u, Column Temperature : 24.6, Total Flow : 4, CO₂ Flow Rate : 2.4, Co-Solvent Flow Rate : 1.6, Co-Solvent % : 40, Back Pressure : 99, RT - 5.8min.

Example 14 (P1 & P2)

2-(4-chlorobenzyl)-4-(3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl)-1,2-oxazinan-3-one



To a solution 2-fluoro-4-(3-fluoropiperidin-4-yl)phenol (0.1 g, 0.469 mmol) in DMF (2 mL) was added DIPEA (0.246 mL, 1.407 mmol) followed by 4-bromo-2-(4-chlorobenzyl)-1,2-oxazinan-3-one (0.214 g, 0.703 mmol) then heated to 120 °C for 90 minutes in microwave. The mixture was allowed to cool to RT. Then concentrated. The crude material was purified via preparative LC/MS with the following conditions: Waters Xbridge C18,19x150mm,5 μ m; Guard Column:Waters XBridge C18,19x10mm,5 μ m; Mobile Phase A:5:95 Acetonitrile:water with 10mM

NH₄OAc; Mobile Phase B: 95:5 Acetonitrile:water with 10mM NH₄OAc; Gradient: 15-50% B over 25minutes, followed by a 10 minute hold at 50% B and 5 minute hold at 100% B; Flow: 15ml/min. Fractions containing the desired product were combined and dried using a Genevac centrifugal evaporator to obtain **14**; 2-(4-chlorobenzyl)-4-(3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl)-1,2-oxazinan-3-one (45mg, 0.093 mmol, 19.77 % yield). The diasteromeric mixture was separated by Chiral HPLC/SFC to get **P1** and **P2**.


SFC Purification condition:

Analytical SFC Conditions : Column/dimensions: Chiralpak OJ-H(250 X 10) 4.6mm,5u , % CO₂ : 70%, % Co solvent: 30%(0.25% DEA in Methanol), Total Flow: 3.0g/min, Back Pressure: 100 bar, Temperature : 25°C, UV: 220,

Preparative SFC Conditions : Column/dimensions: Chiralpak OJ-H(250 X 21)mm,5u, % CO₂: 70%, % Co solvent: 30%(0.25% DEA in Methanol), Total Flow: 60g/min, Back Pressure: 100 bar, Temperature: 25°C, UV: 220, Peak number : 15 Retention Time :: Peak 1 : 6.00 :: Peak 2 : 7.50, Solubility: 20ml in Methanol, Loadability/Inj: 2mg/mL, Total No of injections18. Total Time for purification 2hrs, Instrument details: Make/Model: Thar SFC-80

The compound **16** was separated by SFC obtained **P1**; 2-(4-chlorobenzyl)-4-(3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl)-1,2-oxazinan-3-one (11mg, 0.025 mmol, 5.26 % yield) and **P2**; 2-(4-chlorobenzyl)-4-(3-fluoro-4-(3-fluoro-4-hydroxyphenyl)piperidin-1-yl)-1,2-oxazinan-3-one (13mg, 0.029 mmol, 6.22 % yield).

For P1(homochiral):




25 **LCMS:** Column-Ascentis Express C8 (50X2.1mm-2.7μm), Mphase A : 2%ACN - 98 %H2O-10mM NH4C00H Mphase B : 98%ACN - 2 %H2O-10mM NH4C00H, Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.7 : 100.0 :: 4.0 : 100.0, RT - 1.981min , M+1) - 437.

H-NMR: 400 MHz, CDCl₃: δ 1.79-1.88 (m, 2H), 2.04-2.10 (m, 1H), 2.32-2.37 (m, 1H), 2.61-2.68 (m, 2H), 2.81 (dt, J = 24.40, Hz, 1H), 2.90-2.94 (m, 1H), 3.40-3.43

(m, 1H), 3.64-3.68 (m, 1H), 3.96-4.06 (m, 2H), 4.52-4.64 (m, 1H), 4.72 (s, 2H), 6.92-7.02 (m, 3H), 7.27-7.33 (m, 4H).

Chiral SFC: Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralcel OJ-H(4.6X250)mm,5u, Column Temperature : 24.4, Total Flow : 3, CO2 Flow Rate : 2.1, Co-Solvent Flow Rate : 0.9, Co-Solvent % : 30, Back Pressure : 100, RT- 6.01min.

For P2(homochiral):




10 **H-NMR:** 400 MHz, CDCl₃: δ 1.78-1.88 (m, 2H), 2.05-2.11 (m, 1H), 2.32-2.36 (m, 1H), 2.60-2.75 (m, 2H), 2.84-2.89 (m, 1H), 2.98 (d, J = 2.00 Hz, 1H), 3.30-3.32 (m, 1H), 3.65-3.70 (m, 1H), 3.96-4.05 (m, 2H), 4.51-4.68 (m, 1H), 4.74 (s, 2H), 6.92-7.02 (m, 3H), 7.25-7.31 (m, 4H).

15 **LCMS:** Column-Ascentis Express C8 (50X2.1mm-2.7μm), Mphase A : 2%ACN - 98 %H₂O-10mM NH₄COOH Mphase B : 98%ACN - 2 %H₂O-10mM NH₄COOH, Flow = 1ML/MIN, Time : %B :: 0.0 :: 0.0 :: 1.7 : 100.0 :: 4.0 : 100.0, RT- 1.995min;(M+1)-437.

20 **Chiral SFC:** Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralcel OJ-H(4.6X250)mm,5u, Column Temperature : 24.4, Total Flow : 3, CO2 Flow Rate : 2.1, Co-Solvent Flow Rate : 0.9, Co-Solvent % : 30, Back Pressure : 100, RT- 7.11min.

Example 15 (P1 & P2)

25 **4-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-2-(4-fluorobenzyl)-1,2-oxazinan-3-one**



To a solution of 4-((3S,4S)-3-fluoropiperidin-4-yl)phenol (0.1 g, 0.512 mmol) in DMF (2 mL) was added DIPEA (0.268 mL, 1.537 mmol) followed by 4-bromo-2-(4-fluorobenzyl)-1,2-oxazinan-3-one (0.221 g, 0.768 mmol) then heated to 120 °C for 90 minutes in microwave. The mixture was allowed to cool to RT and then 5 concentrated. The crude material was purified via preparative LC/MS with the following conditions: Waters Xbridge C18,19x150mm,5μm; Guard Column:Waters XBridge C18,19x10mm,5μm; Mobile Phase A:5:95 Acetonitrile:water with 10mM NH4OAc; Mobile Phase B: 95:5 Acetonitrile:water with 10mM NH4OAc; Gradient:15-50% B over 25minutes, followed by a 10 minute hold at 50% B and 5 10 minute hold at 100% B;Flow:15ml/min. Fractions containing the desired product were combined and dried using a Genevac centrifugal evaporator to obtained **15**; 4-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-2-(4-fluorobenzyl)-1,2-oxazinan-3-one (51mg, 0.115 mmol, 22.51 % yield). The diasteromeric mixture was separated by Chiral HPLC/SFC to get **P1** and **P2**.


15 **SFC Purification Method:**

Analytical SFC Conditions: Column/dimensions: Chiralpak OJ-H(250 X 4.6)mm,5u, % CO2: 70%, % Co solvent: 30%(0.25% DEA in Methanol), Total Flow: 3.0g/min, Back Pressure: 100 bar, Temperature : 25°C, UV: 222,

Preparative SFC Conditions: Column/dimensions: Chiralpak OJ-H(250 X 21)mm,5u, % CO2: 70%, % Co solvent: 30%(0.25% DEA in Methanol), Total Flow: 60g/min,Back Pressure: 100 bar, Temperature: 25°C, UV: 222, Peak number : Retention Time :: Peak 1 : 6.00 :: Peak 2 : 7.20, Solubility: 15ml in Methanol, Loadability/Inj: 3mg/mL, Total No of injections 15Total Time for purification 45min, Instrument details: Make/Model: Thar SFC-80.

25 The compound **15** was separated by SFC to obtained **P1**; 4-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-2-(4-fluorobenzyl)-1,2-oxazinan-3-one (9mg, 0.022 mmol, 4.32 % yield) and **P2**; 4-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-2-(4-fluorobenzyl)-1,2-oxazinan-3-one (9mg, 0.022 mmol, 4.28 % yield) .

For P1(homochiral):




30

LCMS: Column-Ascentis Express C8 (50X2.1mm-2.7 μ m), Mphase A : 2%ACN - 98 %H2O-10mM NH4C00H Mphase B : 98%ACN - 2 %H2O-10mM NH4C00H, Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.7 : 100.0 :: 4.0 : 100.0, RT -1.925min, (M+1)-403.

5 **H-NMR:** 400 MHz, CDCl₃: δ 1.84-1.88 (m, 2H), 2.04-2.10 (m, 1H), 2.32-2.37 (m, 1H), 2.64 (dt, J = 26.40, Hz, 1H), 2.79 (dt, J = 24.40, Hz, 1H), 2.92 (d, J = 10.80 Hz, 1H), 3.41-3.43 (m, 1H), 3.64-3.68 (m, 1H), 3.94-4.06 (m, 2H), 4.56-4.70 (m, 1H), 4.72 (s, 2H), 6.80 (td, J = 14.40, Hz, 2H), 7.15 (td, J = 14.00, Hz, 2H), 7.31-7.35 (m, 2H).

10 **Chiral SFC:** Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralcel OJ-H(4.6X250)mm,5u, Column Temperature : 24.3, Total Flow : 3, CO₂ Flow Rate : 2.1, Co-Solvent Flow Rate : 0.9, Co-Solvent % : 30, Back Pressure : 101, RT- 5.86min.

15 **For P2(homochiral):**



15 **LCMS:** Column-Ascentis Express C8 (50X2.1mm-2.7 μ m), Mphase A : 2%ACN - 98 %H2O-10mM NH4C00H Mphase B : 98%ACN - 2 %H2O-10mM NH4C00H, Flow = 1ML/MIN, Time : %B :: 0.0 : 0.0 :: 1.7 : 100.0 :: 4.0 : 100.0, RT-1.923min, (M+1)-403.

20 **H-NMR:** 400 MHz, CDCl₃: δ 1.81-1.87 (m, 2H), 2.06-2.12 (m, 1H), 2.32-2.36 (m, 1H), 2.61-2.66 (m, 1H), 2.71 (dt, J = 24.40, Hz, 1H), 2.84 (dt, J = 22.40, Hz, 1H), 2.99 (d, J = 10.40 Hz, 1H), 3.30-3.33 (m, 1H), 3.65-3.70 (m, 1H), 3.95-4.05 (m, 2H), 4.53-4.66 (m, 1H), 4.72 (s, 2H), 6.80 (d, J = 8.80 Hz, 2H), 7.00-7.05 (m, 2H), 7.15 (d, J = 8.40 Hz, 2H), 7.31-7.34 (m, 2H).









25 **Chiral SFC:** Injection Volume : 10, Co-Solvent : 0.3% DEA in Methanol, Column : Chiralcel OJ-H(4.6X250)mm,5u, Column Temperature : 24.3, Total Flow : 3, CO₂ Flow Rate : 2.1, Co-Solvent Flow Rate : 0.9, Co-Solvent % : 30, Back Pressure : 101, RT - 6.73min.

Biological Methods









Radioligand binding assay. Binding experiments to determine binding to NR2B-subtype NMDA receptors were performed on forebrains of 8-10 weeks old male Sprague Dawley rats (Harlan, Netherlands) using ^3H Ro 25-6981 (Mutel V; 5 Buchy D; Klingelschmidt A; Messer J; Bleuel Z; Kemp JA; Richards JG . *Journal of Neurochemistry* , 1998, 70(5):2147-2155. Rats were decapitated without anesthesia using a Guillotine (approved by animal ethics committee) and the harvested brains were snap-frozen and stored at -80 °C for 3-6 months for membrane preparation.




10 For membrane preparation, rat forebrains were thawed on ice for 20 minutes in homogenization buffer composed of 50mM KH_2PO_4 (pH adjusted to 7.4 with KOH), 1mM EDTA, 0.005% Triton X 100 and protease inhibitor cocktail (Sigma Aldrich). Thawed brains were homogenized using a Dounce homogenizer and centrifuged at 48000 X g for 20 min. The pellet was resuspended in cold buffer and 15 homogenized again using a Dounce homogenizer. Subsequently, the homogenate was aliquoted, snap-frozen and stored at -80 °C for not more than 3-4 months.

20 To perform the competition binding assay, thawed membrane homogenate was added to each well of a 96-well plate (20 $\mu\text{g}/\text{well}$). The experimental compounds were serially diluted in 100% DMSO and added to each row of the assay plate to achieve desired compound concentrations, keeping the DMSO concentration in the assay plate at 1.33 % of the final reaction volume. Next, ^3H Ro 25-6981 (4 nM) was 25 added to the assay plate. After incubation for 1 hr at room temperature, the membrane bound radioligand was harvested on to GF/B filter plates (treated with 0.5% PEI for 1 hr at room temperature). The filter plates were dried at 50 °C for 20 mins, incubated with microscint 20 for 10 minutes and finally, the counts were read 30 on TopCount (Perkin Elmer). Non-specific binding was determined using MK-0657 (the preparation of this compound is described as example 1 in WO 2004 108705 (40 μM). CPM values were converted to % inhibition and the concentration response curves were plotted using custom made software. Each experiment was repeated at least twice to obtain the final binding K_i values for experimental compounds. Using this assay, the compound of example 10 P-1 shows a binding K_i of 3.2 nM.

Example	Structure	NR2B Binding Ki, nM
1, P-1		304.90
1, P-2		4.08
2, P-1		112.30
2, P-2		2.79
3		15.08
4		5.49
5, P-1		143.70
5, P-2		4.37

Example	Structure	NR2B Binding Ki, nM
6,P-1		6.53
6,P-2		8.16
7,P-1		124.80
7,P-2		4.98
8,P-1		57.82
8,P-2		18.75
9,P-1		139.40
9,P-2		12.08
10,P-1		3.20

Example	Structure	NR2B Binding Ki, nM
10,P-2		10.70
11,P-1		3.06
11,P-2		39.34
12,P-1		3.90
12,P-2		149.70
13,P-1		367.20
13,P-2		4.03
14,P-1		98.68

Example	Structure	NR2B Binding Ki, nM
14,P-2		2.80
15,P-1		393.00
15,P-2		12.54

Ex vivo occupancy assay. This assay demonstrates that the compound of example 2P-2 occupies brain-resident NR2B-subtype receptors in animals after dosing. 7-9 weeks old male CD-1 mice were dosed intravenously in a vehicle consisting of 10% dimethylacetamide, 40% PEG-400, 30% hydroxypropyl betacyclodextrin, and 30% water with experimental compounds and the forebrains were harvested 15 minutes post-dosing by decapitation. The brain samples were immediately snap-frozen and stored at -80 °C. On the following day, the dosed brain samples were thawed on ice for 15-20 minutes followed by homogenization using Polytron for 10 seconds in cold homogenization buffer composed of 50 mM KH₂PO₄ (pH adjusted to 7.4 with KOH), 1mM EDTA, 0.005% Triton X 100 and protease inhibitor cocktail (Sigma Aldrich). The crude homogenates were further homogenized using a Dounce homogenizer and the homogenized membrane aliquots from all animals were flash-frozen and stored at -80 °C until further use. The whole homogenization process was performed on ice.

For determining occupancy, the membrane homogenates were first thawed on ice and then needle-homogenized using a 25 gauge needle. The homogenized membrane (6.4 mg/ml) was added to a 96-well plate followed by addition of ³H Ro 25-6981 (6 nM). The reaction mixture was incubated for 5 minutes on a shaker at 4 °C and then

harvested onto GF/B filter plates (treated with 0.5% PEI for 1 hr at room temperature). The filter plates were dried at 50 °C for 20 mins, incubated with microscint 20 for 10 minutes and read on TopCount (Perkin Elmer). Each dose or compound group consisted of 4-5 animals. The control group of animals was dosed 5 with vehicle alone. Membrane from each animal was added in triplicates to the assay plate. Non-specific binding was determined using 10 µM Ro 25-6981 added to the wells containing membrane homogenates from vehicle-dosed animals. Specific counts/minute was converted to % occupancy at each dose of a compound for each animal using the following equation:

10 *% Occupancy (animal A)*

$$= 100 - \left(\frac{\text{specific CPM of animal A}}{\text{Average CPM from control group}} \times 100 \right)$$

Using this procedure, the compound of example 10, P-1 shows 94 % NR2B receptor occupancy after a 3 mg/Kg i.v. dose. Drug levels were determined by mass 15 spectroscopy in the usual manner. Drug levels in the blood plasma were 572 nM in at this dose, and drug levels in the homogenized brain tissue were 863 nM.

hERG electrophysiology assay. The experimental compounds were assessed for hERG activity on HEK 293 cells stably expressing hERG channels using patch clamp technique. Coverslips plated with hERG expressing cells were placed in the 20 experimental chamber and were perfused with a solution composed of (in mM): 140 NaCl, 4 KCl, 1.8 CaCl₂, 1 MgCl₂, 10 Glucose, 10 HEPES (pH 7.4, NaOH) at room temperature. Borosilicate patch pipettes had tip resistances of 2-4 Mohms when filled with an internal solution containing: 130 KCl, 1 MgCl₂, 1 CaCl₂, 10 EGTA, 10 HEPES, 5 ATP-K₂ (pH 7.2, KOH). The cells were clamped at -80 mV in whole cell 25 configuration using an Axopatch 200B (Axon instruments, Union City, CA) patch clamp amplifier controlled by pClamp (Axon instruments) software. Upon formation of a gigaseal, the following voltage protocol was repeatedly (0.05 Hz) applied to record tail currents: depolarization step from -80 mV to +20 mV for 2 seconds followed by a hyperpolarization step to -65 mV (3 seconds) to elicit tail currents and 30 then, back to the holding potential. Compounds were applied after stabilization of tail current. First, tail currents were recorded in presence of extracellular solution alone (control) and subsequently, in extracellular solution containing increasing

compound concentrations. Each compound concentration was applied for 2-5 minutes. The percentage inhibition at each concentration was calculated as reduction in peak tail current with respect to the peak tail current recorded in the presence of control solution. Data analysis was performed in custom made software. The 5 percent inhibitions at different concentrations were plotted to obtain a concentration response curve, which was subsequently fitted with a four parameter equation to calculate the hERG IC₅₀ value. Using this procedure, the compound of example 10,P-1 is a poor inhibitor of the hERG channel, with an IC₅₀ = 30 μ M.

Mouse Forced swim test (mFST). Forced Swim Test (FST) is an animal model 10 used to assess antidepressant compounds in preclinical studies. The FST was performed similar to the method of Porsolt et al. with modifications (Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. *Arch Int Pharmacodyn Thér* 1977; 229:327-36). In this paradigm, mice are forced to swim in an inescapable cylinder filled with water. Under these 15 conditions, mice will initially try to escape and eventually develop immobility behavior; this behavior is interpreted as a passive stress-coping strategy or depression-like behavior. Swim tanks were positioned inside a box made of plastic. Each tank was separated from each other by opaque plastic sheets to the height of cylinders. Three mice were subjected to test at a time. Swim sessions were 20 conducted for 6 min by placing mice in individual glass cylinders (46 cm height X 20 cm diameter) containing water (20-cm deep, maintained at 24-25 °C). At this water level, the mouse tail does not touch the bottom of the container. The mouse was judged to be immobile whenever it remained floating passively without struggling in the water and only making those movements necessary to keep its nose/head above 25 the water and to keep it afloat. The duration of immobility was evaluated during the total 6 min of the test and expressed as duration (sec) of immobility. Each mouse was tested only once. At the end of each session, mice were dried with a dry cloth and returned to their home cage placed on a thermal blanket to prevent hypothermia. Water was replaced after each trial. All testing sessions were recorded with a video 30 camera (Sony Handicam, Model: DCR-HC38E; PAL) and scoring was done using the Forced Swim Scan, Version 2.0 software (Clever Systems Inc., Reston, VA, USA; see Hayashi E, Shimamura M, Kuratani K, Kinoshita M, Hara H. Automated experimental system capturing three behavioral components during murine forced

swim test. *Life Sci.* 2011 Feb 28;88(9-10):411-7 and Yuan P, Tragon T, Xia M, Leclair CA, Skoumbourdis AP, Zheng W, Thomas CJ, Huang R, Austin CP, Chen G, Guitart X. Phosphodiesterase 4 inhibitors enhance sexual pleasure-seeking activity in rodents. *Pharmacol Biochem Behav.* 2011; 98(3):349-55). For NCE testing: Test
5 compound was administered in mice 15 min before swim session by i.v. route and immobility time was recorded for next 6 min. At the end of FST, the mouse were euthanized by rapid decapitation method and plasma and brain samples were collected and stored under -80°C till further analysis. In the mouse forced swim assay, the compound of example 1 was dosed intravenously in a vehicle of 30%
10 hydroxypropyl betacyclodextrin / 70% citrate buffer pH 4 at a 5 mL/Kg dosing volume. The compound of example 10, P-1 demonstrated a statistically significant decrease in immobility time at 1 mg/Kg under these conditions. Drug levels were 207 nM in the plasma at this dose. The NR2B receptor occupancy was determined as reported above and was determined to be 69%.

15


It will be evident to one skilled in the art that the present disclosure is not limited to the foregoing disclosure and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the instant disclosure be considered in all respects as illustrative and not restrictive, 20 reference being made to the appended claims, rather than to the foregoing disclosure, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

25

CLAIMS

We claim:

1. A compound of the formula I



where:

Ar¹ is phenyl and is substituted with 0-3 substituent selected from cyano, halo, alkyl, haloalkyl and haloalkoxy;

Ar² is phenyl, pyridinyl or pyrimidinyl, and is substituted with 1 OR substituent and with 0-2 halo or alkyl substituents;

R is hydrogen or a prodrug moiety selected from the group consisting of alkyl esters, amino acid esters, alkoxy esters, phosphonic acids, phosphonic alkyl esters, alkoxyphosphonate acid, alkoxyphosphonate alkyl esters, alkyl carabamates, amino acid carbamates, alkyl phosphoramidates, aryl phosphoramidates, and sulfamates;

X is a bond or C₁-C₃ alkylene;

n is 1 or 2;

ring A is piperidine, piperazine and is substituted with 0-1 halo substituents;

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 where Ar¹ is phenyl and is substituted with 0-1 substituent selected from halo and alkyl; Ar² is phenyl, pyridinyl or pyrimidinyl, and is substituted


with 1 OR substituent and with 0-2 halo or alkyl substituents; R is hydrogen; X is a bond or C₁-C₃ alkylene; n is 1 or 2; ring A is piperidine, piperazine and is substituted with 0-1 halo substituents; or a pharmaceutically acceptable salt thereof.

3. A compound of claim 2 where Ar¹ is phenyl and is substituted with 0-1 substituent selected from halo and alkyl; Ar² is phenyl or pyridinyl, and is substituted with 1 OR substituent and with 0-1 halo substituents; R is hydrogen; X is a methylene; n is 1 or 2; ring A is piperidine or piperazine and is substituted with 0-1 halo substituents; or a pharmaceutically acceptable salt thereof.

4. A compound of claim 1 where n is 1 and ring A is piperazine or piperidine substituted with 0-1 fluoro.


5. A compound of claim 1 where Ar¹ is phenyl substituted with 0-1 substituents selected from chloro, fluoro and methyl.


6. A compound of claim 1 where Ar² is selected from












7. A compound of claim 1 where X is methylene.

8. A compound of claim 1 selected from the group consisting of









or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

10. A method for the treatment of depression, Alzheimer's disease, neuropathic pain, or Parkinson's disease, which comprises administering to a patient a therapeutically affective amount of a compound of claim 1.

11. The method of claim 11 directed to the treatment of depression.

12. The method of claim 11 directed to the treatment of Alzheimer's disease.

13. The method of claim 11 directed to the treatment of neuropathic pain.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2016/056716

A. CLASSIFICATION OF SUBJECT MATTER				
INV.	C07D413/14	C07D413/04	A61K31/454	A61K31/4439
	A61K31/496	A61P25/02	A61P25/16	A61P25/28

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2015/105772 A1 (SQUIBB BRISTOL MYERS CO [US]) 16 July 2015 (2015-07-16) the whole document -----	1-13
A	WO 2015/105929 A1 (SQUIBB BRISTOL MYERS CO [US]) 16 July 2015 (2015-07-16) the whole document -----	1-13
A	WO 2011/100585 A1 (MOSKAL JOSEPH [US]; KHAN AMIN [US]) 18 August 2011 (2011-08-18) paragraphs [0032], [0076] - paragraph [0077] -----	1-13



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

11 January 2017

18/01/2017

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Von Daacke, Axel

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2016/056716

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 2015105772	A1 16-07-2015	AU 2015205001	A1	18-08-2016	
		CA 2936293	A1	16-07-2015	
		CN 106061961	A	26-10-2016	
		EA 201691413	A1	31-10-2016	
		EP 3092224	A1	16-11-2016	
		KR 20160105885	A	07-09-2016	
		SG 11201605618W	A	30-08-2016	
		TW 201613884	A	16-04-2016	
		US 2015191452	A1	09-07-2015	
		US 2016081995	A1	24-03-2016	
		UY 35947	A	31-07-2015	
		WO 2015105772	A1	16-07-2015	
<hr/>					
WO 2015105929	A1 16-07-2015	AU 2015204785	A1	25-08-2016	
		CA 2936338	A1	16-07-2015	
		CN 105873915	A	17-08-2016	
		EP 3092223	A1	16-11-2016	
		KR 20160101194	A	24-08-2016	
		SG 11201605620Q	A	30-08-2016	
		TW 201612169	A	01-04-2016	
		US 2015191496	A1	09-07-2015	
		US 2016030456	A1	04-02-2016	
		UY 35946	A	31-07-2015	
		WO 2015105929	A1	16-07-2015	
<hr/>					
WO 2011100585	A1 18-08-2011	AU 2011215704	A1	30-08-2012	
		CA 2789331	A1	18-08-2011	
		CN 102933226	A	13-02-2013	
		CN 105037492	A	11-11-2015	
		EP 2542254	A1	09-01-2013	
		IL 221400	A	31-07-2016	
		JP 5928828	B2	01-06-2016	
		JP 2013519683	A	30-05-2013	
		JP 2016185948	A	27-10-2016	
		RU 2012138710	A	20-03-2014	
		SG 183265	A1	27-09-2012	
		SG 10201501050R	A	29-04-2015	
		US 2013053325	A1	28-02-2013	
		US 2016115197	A1	28-04-2016	
		WO 2011100585	A1	18-08-2011	
<hr/>					